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AIM OF THE STUDY 
Systemic sclerosis (SSc) is a chronic autoimmune condition characterized by excessive tissue 
fibrosis, microvascular alterations and immune dysfunction with the production of characteristic 
autoantibodies. These autoantibodies are highly specific for SSc diagnosis, and provide the most 
reliable tool to predict disease subset and the pattern of internal organ involvement. Despite such 
diagnostic and prognostic role, no evidence supporting the pathogenic potential of these 
autoantibodies has to date been raised. The working hypothesis of this study envisaged that immune 
complexes (ICs) containing scleroderma specific autoantibodies -rather than the mere antibody- 
might be able to elicit a proinflammatory and pro-fibrotic signaling cascade in target cells, thus 
contributing to SSc multifaceted etiopathogenesis. Since scleroderma autoantibodies bind –either 
directly or via bridge proteins- to nucleic acids, it was also postulated that the effects induced by 
SSc-ICs might be mediated by Toll-like Receptors (TLR).  
MATERIALS AND METHODS 
Fibroblasts have been isolated from skin biopsies from healthy controls and then cultured in 
adequate conditions. ICs have been purified from sera of scleroderma patients bearing different 
autoantibody specificities (antibodies against centromeric proteins [ACA], DNA topoisomerase I 
[ATA], RNA polymerase [ARA] and Th/To [anti-Th/To]) or of healthy controls using polyethylen 
glycol precipitation. Fibroblasts were transiently silenced for tlr3 using a specific small interfering 
RNA (siRNA); silencing was confirmed by RT-PCR and Western Blotting. Naïve and tlr3-silenced 
cells have been incubated with pathologic and control ICs and with TLR3 [Poly(I:C)] and TLR4 
(LPS) agonists. Several parameters of cell activation have been assessed in the different 
experimental conditions. In particular, mRNA levels of type I interferons (IFN-α and IFN-β) and 
TLR (TLR3 and TLR9) have been investigated by real-Time PCR; ICAM-1 expression has been 
evaluated by cell-ELISA and the secretion of IL-6 and IL-8 in culture supernatants has been 
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measured by commercial ELISA kits. Furthermore, the involvement of intracellular signaling 
pathways culminating with the activation of p38 MAPK and NFκB has been assessed.  
RESULTS 
Stimulation of normal skin fibroblasts with pathologic ICs induced a significant increase in the gene 
expression levels of both IFN-α and IFN-β; similar results have been reported in the presence of 
TLR agonists but not of control ICs and medium alone. In addition, ICAM-1 expression and IL-6 
and IL-8 secretion were up-regulated by Poly(I:C), LPS and ICs from scleroderma patients but not 
healthy controls and medium alone. Further, pathologic ICs induced the activation of both p38 
MAPK and NFκB. The expression levels of TLR3 and -to a greater extent- TLR9  were 
significantly increased in cells treated with TLR3 agonist and ICs from SSc patients but not healthy 
controls.  The efficiency of tlr3 silencing in skin fibroblasts was confirmed at both mRNA and 
protein levels. tlr3 silencing significantly affected ICAM-1 expression and IL-6, but not IL-8, 
secretion in cells treated with both TLR agonists and ICs from SSc patients but not healthy controls 
and medium alone. 
CONCLUSIONS  
These data provide the first demonstration of the pathogenic role of ICs isolated from scleroderma 
patients with different autoantibody specificities in the inductor phase of SSc. Indeed, pathologic 
ICs can interact with normal skin fibroblasts, inducing a pro-inflammatory phenotype mediated by 
p38 MAPK and NFκB. In particular, ICs isolated from SSc patients have been shown to recruit 
TLR3 leading to fibroblast activation, with upregulation of adhesion molecules and secretion of 
pro-inflammatory interleukins. Other TLRs, such as TLR7, TLR8 and TLR9, might be implicated 
in the cell response to scleroderma ICs. These evidences fit well with the diagnostic and prognostic 
role of scleroderma-specific autoantibodies. 
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Systemic sclerosis: clinical features 
 
Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology. This condition was 
first described in 1753 by Carlo Curzio, a Neapolitan physician. It is also known as scleroderma, 
from the ancient greek words “” (tight) and “” (skin); this term was coined in 1847 
by Gintrac
1
. SSc is indeed characterized by an excessive deposition of collagen and other 
components of the extra-cellular matrix (ECM) in the skin and other target organs, which in turns 
leads to tissue fibrosis. Scleroderma is a systemic disease: besides the skin, it most commonly 
affects the gastrointestinal tract, the lungs and the kidneys.  
 
 Epidemiology 
SSc is a rare clinical condition, with an estimated incidence of 19 cases per 1.000.000 inhabitants 
per year; disease prevalence ranges between 4 and 286 cases per million. The highest prevalence of 
SSc has been reported in the Choctaw native American tribe in Oklahoma: 469 cases per 100.000 
subjects
2
.  
Scleroderma mainly affects women, with a male/female ratio of 1:3-5; female preponderance is 
most marked during childbearing years, narrowing towards the fifth decade to 1:2-3. The disease 
onset occurs most commonly between 30 and 50 years of age, with an average of 42 years among 
Caucasian women
3
.   
The risk of developing SSc has been related to the occupational exposure to silica dust and organic 
solvents; in particular, a high final cumulative exposure to crystalline silica, trichlorethylene, 
chlorinated solvents, welding fumes, and any types of solvents was found to be associated with SSc. 
Occupational exposure-related SSc is more common among men, being characterized by a severe 
skin thickening and a mild organ involvement
4
. 
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 Survival 
SSc diagnosis carries an increased mortality, with a 4.6 fold risk of death compared to the general 
population. The average life expectancy in SSc patients is 16-34 years less than matched controls. 
In one study, the survival rates at 5 and 10 years were 86% and 69% respectively
5
. In addition, 
prognosis is worse in men compared to women, in older subjects compared to youngsters. Several 
predictors of survival have been identified: extensive skin involvement, cardiopulmonary disease, 
renal involvement and positivity for anti-DNA topoisomerase I antibodies (ATA). In particular, 
pulmonary artery hypertension (PAH) and interstitial lung disease (ILD) are the two leading causes 
of SSc-related mortality, with a pooled standardized mortality ratio of 3.5 and 2.6 respectively
6
.   
 
 Classification criteria for systemic sclerosis  
A joint committee of the American College of Rheumatology (ACR)/ European League against 
Rheumatism (EULAR) has recently proposed new classification criteria for SSc
7
. 
The skin thickening of the fingers proximal to the metacarpophalangeal joints is regarded as a 
sufficient criterion for classifying the patient as having SSc. If this criterion is not present, seven 
additional items are then considered: 
- Skin thickening of the fingers 
o Sub-items: Puffy fingers/Sclerodactily of the fingers 
- Fingertip lesions 
o Sub-items: Digital tip ulcers/Fingertip pitting scars 
- Teleangiectasias 
- Abnormal nailfold capillaries 
- ILD or PAH 
- Raynaud‟s phenomenon 
- SSc-related autoantibodies  
17 
 
A score ranging from 2 to 4 has been appointed to each additional item; patients with a total 
score above 9 are classified as having definite SSc. In the validation sample, this set of criteria 
displayed a sensitivity of 0.91 with a specificity of 0.92
7
.  
 
 Disease subsets 
In 1988, Carwile LeRoy proposed to identify two disease subsets according to the extent of the 
skin thickening
8
. Diffuse cutaneous SSc (dcSSc, 35% of SSc patients) is characterized by a 
cutaneous involvement affecting the face, the trunk, the thighs and the arms. In the limited form 
of the disease (lcSSc, 60% of SSc patients), the skin of the trunk and the proximal portions of 
the limbs are spared. dcSSc and lcSSc differ also with regards to the pattern of organ 
involvement and autoantibody profile. Patients with dcSSc are at higher risk of developing 
clinically significant major internal organ dysfunction. In particular, ILD and scleroderma renal 
crisis (SRC) are more common in the diffuse subset, while patients with limited disease 
frequently develop PAH. dcSSc is associated with positivity for ATA, patients with the limited 
form are more likely to carry anti-centromere antibodies (ACA)
9
. Mortality is higher in dcSSc 
compared to lcSSc, with a median disease duration from onset of Raynaud‟s phenomenon to 
death of 7.1 years and 15.0 years respectively
5
. 
In a third variant of the disease (5% of patients with SSc), namely SSc sine scleroderma, 
patients develop vascular and fibrotic damage to internal organs associated with SSc-
autoantibodies, in the absence of any skin thickening
10
. 
SSc can also be associated with manifestations of other connective tissue diseases (CTDs): these 
clinical entities are referred to as overlap syndromes (SSc/rheumatoid arthritis overlap 
syndrome, SSc/myositis overlap syndrome…)11.    
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 Clinical manifestations 
 
o Raynaud’s phenomenon 
Raynaud‟s phenomenon is secondary to transient episodes of vasospasm of peripheral small vessels 
as arteries, arterioles, pre- and post-capillary venules. It can be clinically characterized by triphasic 
(pallor in the ischemic phase, cyanosis in the deoxygenation phase, and erythema in the reperfusion 
phase) or bifasic (pallor and cyanosis or cyanosis and erythema) colour changes. Typically, it 
involves fingers and toes and, much less commonly, the nose, the earlobes and the tongue. Episodes 
can be triggered by the exposure to cold conditions, emotional stress, pharmacological agents, and 
vibratory injuries. Raynaud‟s phenomenon represents the first manifestation of the disease in 95% 
of scleroderma patients. Together with PAH and SRC, it is a clinical expression of scleroderma 
vasculopathy: vessels display fibrotic intimal hyperplasia, adventitial fibrosis and reduced arterial 
lumen. In patients with limited scleroderma, Raynaud‟s phenomenon might precede by several 
years the onset of cutaneous and internal organ involvements. Conversely, dcSSc patients present 
an abrupt onset of Raynaud‟s phenomenon, shortly followed by other manifestations of the 
disease
12
.    
In scleroderma patients, attacks are usually asymmetric, intense, frequent and painful. Episodes 
might result in impaired oxygenation of the distal extremities leading to digital ulcers of both 
fingers and toes in 30% of patients. Ulcers can also manifest over the finger creases, the extensor 
surface of joints or over the site of calcium subcutaneous deposits. Acral skin ulcerations might 
resolve with hyperkeratosic pitting scars. Severe cases might also evolve to necrosis and dry 
gangrene; in these situations, acral bone resorption and self-amputation of the phalanges can occur. 
Chronic ulcers might become infected, then resulting in gangrene and osteomyelitis
13
.  
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o Skin involvement 
Cutaneous involvement is the clinical hallmark of SSc. It usually begins with an early phase of skin 
oedema, manifesting as swollen fingers and hands. Fibrosis appears later: skin becomes hardened, 
with the loss of its natural pliability; appendages degenerate leading to hair loss and anhidrosis. In 
the later stages, atrophy supervenes: the skin gets thin and dry.    
Skin thickening usually starts from the fingers and evolves with a distal to proximal pattern. In the 
active phase of the disease, the skin darkens, is shiny and itchy. A “salt and pepper” appearance 
may result from patchy hypo and hyperpigmented area. The extent of skin thickening may vary 
widely: some patients present sclerodactyly only, whereas in most severe forms skin thickening 
might affect the whole integument, with joint mobility limitation and development of flexion 
contractures. Peri-oral fibrosis leads to microcheily, reduced mouth aperture and microglossy, the 
nose is pinched, the appearance is expressionless: the typical “scleroderma facies”. Telangiectasias, 
which are dilated superficial blood vessels, can be observed on the fingers, palms, lips, face, tongue 
and in the mouth; telangiectasias are more commonly reported in the limited form of the disease
14
. 
An additional skin finding in SSc is calcinosis cutis, due to the deposition of calcium 
hydroxyhepatite crystals in the soft tissues. Usually it occurs at pressure points, typically the 
extensor surface of hand joints, but also of forearms, buttocks and other body areas. These lesions 
might extrude from the skin and ulcerate
14
.  
The modified Rodnan skin score (mRSS) is a semi-quantitative method to assess skin thickening. It 
considers 17 anatomic areas, and rates each area by clinical palpation using a 0–3 scale (0=normal 
skin; 1=mild thickness; 2=moderate thickness; 3=severe thickness with inability to pinch the skin 
into a fold)
15
. A mRSS over 20 has been shown to predict heart involvement, SRC and an increased 
mortality risk.   
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o Gastrointestinal involvement 
Gastrointestinal symptoms usually occur early on disease course, often being the presenting event 
after Raynaud‟s phenomenon. The gastrointestinal tract is the most affected organ after the skin: 
95% of SSc patients present gastrointestinal involvement. Approximately half of these patients 
complain of clinical symptoms, 10% display severe manifestations. Any tract, from the mouth to 
the anus, might be affected; consequently, gastrointestinal manifestations may vary greatly, ranging 
from bloating and heartburn to dysphagia and anorectal dysfunction to severe weight loss and 
malabsorption. Gastrointestinal involvement exerts a strong impact on patients‟ quality of life, even 
though it is rarely the cause of death
16
.  
Esophageal dysmotility can be detected in 90% of patients, with an alteration of peristaltic activity 
of the smooth muscle of the distal two thirds of the oesophagus and an impaired barrier function of 
the lower esophageal sphinctera. Clinically, it manifests with gastroesophageal reflux and 
dysphagia. Chronic reflux may be complicated by esophageal strictures and Barrett‟s metaplasia of 
the distal esophagus. Approximately half of patients complain of gastroparesis symptoms: nausea, 
vomiting, weight loss, early satiety, bloating or epigastric pain. In turn, delayed gastric emptying 
can worsen reflux symptoms. Gastric antral vascular ectasia (GAVE) represents an additional 
vascular complication of scleroderma. GAVE displays a unique endoscopic appearance, known as 
“watermelon stomach”: longitudinal stripes of red vessels radiate from the pylorus to the antrum. 
Estimated prevalence of GAVE in SSc ranges from 1.8% to 22.3%; it is often a cause of significant 
bleeding. Positivity for anti-RNA polymerase III antibodies (ARA) has been reported as an 
independent risk factor for GAVE development
17
.  
Bloating and postprandial fullness may also indicate small bowel involvement, which has been 
described in 20-60% of scleroderma patients. Most commonly, patients notice new onset nutritional 
intolerances, typically lactose intolerance. Impaired motility leads to stasis of luminal contents, 
which in turn induces secondary bacterial overgrowth; the frequent use of acid suppressive 
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medication for reflux disease may contribute to the development of bacterial overgrowth. Bacterial 
overgrowth can cause malabsorption, which is considered a poor prognostic factor: mortality rate at 
8 years is 50%. Small bowel involvement might be further complicated by pseudo-obstruction
18
.  
Colorectal involvement can be detected in 10-50% of patients; the anorectal tract is mostly affected. 
Clinical manifestations include constipation, diarrhea and/or fecal incontinence
16
. 
Approximately 8% of patients with limited SSc carry anti-mitochondria antibodies (AMA); on the 
other hand, ACA can be detected in 9-29% of patients with primary biliary cirrhosis. All 
scleroderma patients with positive AMA display a certain degree of cholestasis with damage of 
small intra-hepatic bile ducts
19
.    
 
o Lung involvement 
Lung involvement is the second most common visceral complication among SSc patients, its 
prevalence ranges between 25 and 90%, depending on the detection method. Due to advances in the 
management of renal complications, lung disease including ILD and PAH has emerged as the 
leading cause of mortality in SSc: up to 30% of deaths are directly attributable to lung fibrosis. The 
most rapid decline in lung function occurs in the first three years from disease onset: 42% of 
patients with SSc-ILD die of disease progression within 10 years from diagnosis
20,21
.    
Some studies suggest that ILD is more common among patients with diffuse subset than limited 
cutaneous SSc: in a 2003 study, lung function tests demonstrated a restrictive pattern in 23% of 
patients with limited disease and in 40% of those with the diffuse subset
22
. The autoantibody profile 
is strongly predictive of the risk of developing ILD: ATA, anti-Th/To, anti-U11/U12 and anti-Pm/Scl 
antibodies are associated with an increased hazard whereas ACA positivity confers relative 
protection from SSc-associated pulmonary fibrosis
23
. Noteworthy, neither the extent of cutaneous 
involvement nor the antibody profile can differentiate between moderate and severe restrictive 
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disease
24
. ILD manifests clinically with dyspnea, often associated with dry cough. Pulmonary 
function tests show a restrictive pattern, with reduced respiratory volumes and impaired diffusion 
capacity. The most frequently noted histopathological picture is non-specific interstitial 
pneumonitis (NSIP, 76% of patients, with isolated ground-glass pattern of opacification on high-
resolution computed tomography [HRCT]); an histologic finding suggestive of usual interstitial 
pneumonia (UIP) is described in 13% of cases, generally associated with a reticular HRCT 
pattern
25
. Not all patients with deterioration in pulmonary function tests have a progressive disease: 
30% of patients develop progressive lung disease and only 16% will develop severe lung fibrosis
26
.   
Approximately 60% of SSc subjects display bronchiectasis, which leads to an increased infective 
risk. Pleural effusion is an uncommon finding in scleroderma patients, being reported in 10% of 
patients
20
. 
 
o Renal involvement 
At autoptic studies, 60-80% of SSc patients were found to have a renal involvement. Indeed, 
moderate clinical manifestations of kidney impairment are frequent among SSc patients: arterial 
hypertension, mild proteinuria, raised creatininemia
27
.  
Differently, SRC is a life-threatening complication of SSc, characterized by an abrupt onset of 
moderate to severe arterial hypertension associated with progressive renal failure
28
.
 
SRC presents in 
10-20% of patients with diffuse disease, much less commonly in the limited subset. It occurs early 
in the disease course, almost invariably within the first five years from diagnosis. Up to 25% of 
patients are diagnosed with SSc at SRC onset
29
. Medium-high dose corticosteroids have been linked 
to SRC, with 60% of patients having received steroids prior to presentation. ARA provide a well-
described risk factor for SRC development: in one scleroderma cohort, approximately 60% of 
patients experiencing SRC harboured ARA. Conversely, ATA and ACA are considered to be 
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protective against the development of SRC. Additional SRC risk-factors include: female gender, a 
severe diffuse skin involvement, recent onset anaemia, pericardic effusion and joint contractures
30
. 
SRC is regarded as a vascular complication of SSc: intima walls of interlobular arteries present the 
typical onion-skin lesions, which lead to the narrowing of the lumen with the consequent reduction 
of blood flow. The introduction of angiotensin-converting-enzyme inhibitors (ACEIs) in the 
pharmacological management of SRC has dramatically improved disease history: survival at 1 year 
has increased from 15 to 76%
30
. However, SRC still carries a poor prognosis, with a mortality rate 
at 5 years ranging between 30 and 40%
29,31
. Haemodialysis is required in two thirds of patients, 
approximately half of subjects on renal replacement therapy then discontinue dialysis
32
. In a UK 
cohort, median time to dialysis discontinuation was 11 months, renal recovery is uncommon after 
24 months
29
.  
 
o Heart involvement 
Primary cardiac involvement is common in SSc although often clinically occult: its prevalence 
among scleroderma patients depends on the sensitivity of the diagnostic tools, ranging from 10 to 
75%
33
. It is more prevalent in the diffuse subset than in the limited form (32% versus 23%)
34
; in 
particular, diffuse patients with a rapid skin thickening rate are at higher risk. To note, ATA 
positivity has been associated with conduction disturbances while anti-U3RNP positive patients are 
at higher risk of myocardial involvement
23,35
. Cardiac involvement usually occurs early on disease 
course, most commonly within 3 years from the diagnosis
34
. Scleroderma heart disease is thought to 
be mediated by a chronic vasospasm of small coronary arteries and arterioles, with a secondary 
ischemia/reperfusion injury, which in turn leads to tissue fibrosis. Fibrotic changes follow a patchy 
distribution, with a mosaic pattern unrelated to large coronary artery distribution. Scleroderma 
disease can involve myocardium, coronary arteries, pericardium and the conduction system: the 
clinical spectrum of scleroderma heart disease is thus heterogeneous
36
. Diastolic dysfunction is the 
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most frequently described feature (17.4%), systolic dysfunction is a much rarer finding. Atrial and 
ventricular tachyarrhythmias result from myocardial fibrosis whereas conduction defects and 
bradyarrhythmias are a consequence of conduction system fibrosis. Supraventricular arrhythmias 
are more common than those of ventricular origin, and occur in two thirds of cases. Conduction 
system involvement is rather uncommon, and rarely clinically manifest. Valvular disease has been 
noted in SSc patients, mainly involving mitral and aortic valves; valvular vegetations provide a rare 
finding. Inflammation may also play a role in SSc cardiac disease: a myocarditis -an acutely 
deteriorating cardiac failure with persistent troponin leakage- has been occasionally reported in SSc 
patients with severe symptoms, and might evolve into restrictive cardiomyopathy and heart 
failure
33
. Endocarditis may develop in association with severe myocarditis. A pericardial disease is 
clinically evident in 5-16% of SSc patients, presenting as pericarditis, pericardial adhesions, 
pericardial effusion and –much rarely- pericardial tamponade and constrictive pericarditis. Reports 
about the prevalence of coronary artery atherosclerosis in SSc patients are conflicting: some studies 
observed a prevalence similar to that of the general population, other authors found an higher 
prevalence
37
. Heart involvement is recognized as a poor prognostic factor: the annual mortality rate 
attributable to cardiac disease is 1%; at ten year follow-up, disease mortality is 20%
38
. 
 
o Pulmonary artery hypertension 
PAH is a haemodynamic condition characterized by a mean pulmonary artery pressure (mPAP) 
above 25 mmHg with a pulmonary capillary wedge pressure < 15 mmHg at right heart catheterism. 
PAH prevalence in SSc ranges between 10 and 12%; 57% of SSc-PAH patients have limited 
disease. It is a late complication of scleroderma, with a median time from SSc diagnosis to PAH 
onset of 10 years
39
.  
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PAH ethiopathogenesis is mediated by the vascular remodeling of pulmonary vessels of 
small/medium size: inflammation induces cell proliferation and an unbalance between 
vasoconstrictor and vasodilator mediators, ultimately leading to increased pulmonary vasculature 
resistance. Patients with PAH complain of progressive dyspnea, fatigue and chest palpitation.   
The gold standard for PAH diagnosis is provided by right heart catheterism, which allows an 
accurate measurement of pulmonary artery haemodynamics. Transthoracic echocardiography 
allows to indirectly estimate the systolic pulmonary artery pressure and is routinely used as a 
screening tool in the whole SSc population. Pulmonary function tests might suggest an underlying 
PAH when the diffusing capacity of the lung for carbon monoxide (DLCO) is markedly reduced. 
Recently, the DETECT study has elaborated an algorithm to identify patients at risk of PAH who 
should undergo echocardiography. This algorithm includes the following variables: ACA positivity, 
right axis deviation at electrocardiogram, serum urate, N-terminal of the prohormone brain 
natriuretic peptide (N-TproBNP) levels, telangiectasias and forced vital capacity (FVC)/DLCO 
ratio
40
. PAH provides the leading cause of mortality among scleroderma patients: a 50% mortality 
rate is registered at 3 years from diagnosis, with a median survival of 2.5 years
41
. 
 
o Articular involvement 
Approximately 12-65% of patients complain of arthralgias at disease onset; the rate increases up to 
46-97% during disease course. An inflammatory arthritis is rarely described. Articular involvement 
is more common among patients with diffuse disease compared to those with lcSSc; subjects with 
positivity for rheumatoid factor are at increased risk of developing articular involvement
42
.   
Skin thickening and tendon fibrosis may result in joint contractures; flexion contractures of fingers, 
wrists, elbows and shoulders have all been reported. Fibrosis of tendinous structures might become 
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apparent as tendon friction rubs, which were described by Rodnan and Medsger as a „leathery, 
crepitus feel‟ perceived on palpation during active or passive articular motion.    
Tendon friction rubs have been described to occur in the early stages of the disease, being 
associated with disease activity and systemic inflammation. They are regarded as a poor prognostic 
factor, being predictive of future development of renal, cardiac and gastrointestinal involvement
43
. 
 
o Muscle involvement 
Scleroderma myopathy is a rather heterogeneous clinical entity, including both fibrotic and 
inflammatory cases. Muscle weakness of non-inflammatory nature is a common complaint in SSc, 
being reported by 60-80% of SSc patients. It typically affects the proximal muscles, being usually 
associated with a moderately elevated aldolase and, less frequently, creatine kinase. Histologic 
findings comprise interstitial and perivascular fibrosis, myofibril atrophy and necrosis. Clear cases 
of inflammatory myopathy, not distinguishable from polymyositis, develop in approximately 6 to 
12% of cases. A strong association between scleroderma/myositis overlap syndrome and positivity 
for anti-Pm/Scl antibodies has been confirmed in many studies
44
.   
 
 Autoantibodies 
Autoantibodies against a wide array of self-antigens have been described in SSc. Approximately 
90% of scleroderma patients display anti-nuclear antibodies (ANA) reacting against various cellular 
components. ACA and ATA are the most frequent scleroderma-specific autoantibodies, providing 
half of the autoantibody specificities detected among SSc patients. Antibodies producing a 
nucleolar staining in indirect immunofluorescence on human epithelioma type 2 (HEp-2) cells – 
ARA, anti-Th/To, anti-U1RNP and anti-U3RNP antibodies- are described less commonly in SSc 
27 
 
patients
35
. These autoantibodies are highly specific for scleroderma, being rarely detected in healthy 
subjects and in patients with other systemic autoimmune conditions. Autoantibody fine specificity 
is usually exclusive. The diagnostic and prognostic role of scleroderma-specific autoantibodies is 
supported also by the recent incorporation of the serum positivity for ATA, ARA and ACA in the 
new criteria for SSc classification
7
.  
Interestingly, the prevalence of each specific SSc-associated autoantibody depends on the 
geographic regions, possibly because of the different genetic and environmental factors. Indeed, 
each autoantibody positivity has been associated with a characteristic HLA asset
45
.     
The detection of scleroderma-specific autoantibodies allows to risk-stratify scleroderma patients at 
disease presentation. Interestingly, it is increasingly recognized that antibody levels may vary over 
time, correlating with disease activity.    
 
o Anti-centromere antibodies 
ACA react against at least six centromeric polypeptides (CENP-A, CENP-B, CENP-C, CENP-D, 
CENP-E and CENP-F). The most common antigenic target is provided by CENP-B, an 80 kDa 
haploid protein that binds to highly repetitive-satellite DNA through a highly conserved 17 base 
pair sequence known as CENP-B box
35
. The CENP-B box contains CpG-rich sequences, which, 
especially if demethylated, can stimulate the production of IFN-. ACA display a very high 
specificity for SSc (99.9%), with a sensitivity of 33%. ACA positivity is detected in 20-30% of SSc 
patients. ACA are strongly associated with limited subset, even though a small proportion (5-7%) of 
ACA positive subjects develop a diffuse disease
46
. ACA have been linked to a greater lag time to 
overt clinical disease compared to other autoantibodies. ACA predict subcutaneous calcinosis, PAH 
and gastrointestinal involvement. Patients with ACA are at increased risk of developing primary 
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biliary cirrhosis. On the other hand, ACA have been found to be protective against the development 
of SRC, ILD, synovitis, tendon friction rubs, joint contractures and myopathy
23
.  
 
o Anti-DNA topoisomerase I antibodies 
ATA target the enzyme DNA topoisomerase I, a 100 kDa chromatin-associated enzyme involved in 
supercoiled DNA relaxation. They were first named anti-Scl-70 as they were found to react against 
a 70 kDa protein by immunoblotting. It was later acknowledged that the 70 kDa protein was a 
breakdown product of a native full-length 100 kDa protein, topoisomerase I, an enzyme located in 
the nucleus and in the nucleolus
35
. ATA are very specific for SSc (97-100%), but sensitivity is 
rather low (9-20%). The prevalence of ATA in SSc cohort has been reported to be 9-39%; ATA are 
strongly associated with diffuse subset, being detected in approximately 40% of dcSSc patients. 
Less than 10% of ATA-positive patients develop the limited disease
46
. ATA positivity has been 
shown to correlate with the severity and the activity of the disease. ATA are also predictors of the 
development of ILD and digital ulcers, but appear to be protective against PAH
23
.   
 
o Anti-RNA polymerase antibodies 
ARA target RNA polymerase I and III, enzymes that catalyze the replication of RNA from an RNA 
template. RNA polymerase I has a nuclear localization, whereas RNA polymerase III is a nucleolar 
enzyme
35
. ARA are extremely specific for SSc (97-100%). ARA frequency in SSc has been 
reported between 4 and 25% of the total cohort, and is described much less commonly in European 
SSc cohort as compared with North American populations
23
. A strong association of ARA with 
diffuse subset has been recognized: 67-93% of ARA positive patients develop dcSSc. In particular, 
ARA positivity has been linked to severe cutaneous involvement, with flexion contracture of hands 
and tendon friction rubs. ARA provide one of the strongest risk factor for SRC: 43% of patients 
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carrying ARA develop SRC, 59% of patients diagnosed with SRC display ARA. ARA confer also 
an increased hazard of GAVE
17
. On the other hand, ARA were found to protect against ILD and 
inflammatory myopathy
23
. ARA levels were reported to fluctuate over time, reflecting changes in 
the skin score
47
. 
An increasing burden of evidence points towards an association between ARA positive SSc and 
cancer. Indeed, malignancy rate is higher in patients with ARA compared to those without ARA 
(44% versus 9-11% in the work by Airo‟48 and 26% versus 13% in another study by Moinzadeh49). 
In particular, Shah and coworkers observed a close temporal relation between cancer and SSc onset 
in patients with ARA: the first SSc symptoms manifest shortly after cancer (mainly breast tumours) 
diagnosis
50
.    
 
o Anti-Th/To antibodies 
Anti-Th/To antibodies target small ribonuclear proteins associated with RNA fragments (H1/8-2 
and Th/7-2 RNA), which are components of the RNA processing enzymes RNase P and RNase 
MRP. This multi-protein-RNA complex consists of a catalytic RNA and several protein 
components
35
. Anti-Th/To are highly specific for SSc, and are detected in 2-5% of patients
23
. 
Cutaneous involvement is usually limited, positivity for anti-Th/To correlates with severe ILD and 
carries an increased mortality hazard
46
.   
 
o Anti-RNP antibodies 
Anti-RNP antibodies are directed against components of the spliceosome, a mithocondrial 
ribonucleoprotein complex involved in pre-mRNA processing into mature RNA. The antigenic 
determinants of the complex are provided by ribonucleoproteins processed with small RNA 
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molecules of 80-350 nucleotides
35
. Antibodies against U1RNP can be detected in 6% of scleroderma 
patients, whereas anti-U3RNP antibodies (formerly known as anti-fibrillarin) can be recognized in 
8% of SSc subjects. Anti-fibrillarin antibodies are more common in the diffuse subset; 50-60% of 
positive patients are of afro-american origin
46
. Antibodies against U3RNP have been shown to 
predict the development of inflammatory myopathy: 23-33% of patients with anti-U3RNP develop a 
muscle disease as compared to 14% of those with other autoantibody specificities
23
. Anti-U3RNP 
antibodies have also been associated with gastrointestinal involvement and PAH
51
.  
 
 Genetics 
The incidence of SSc is higher in families where a relative holds a scleroderma diagnosis (1.5-1.7% 
versus 0.026% in the general population). The relative risk of developing scleroderma is increased 
by 15 to 19-fold for siblings of SSc patients and by 13 to 15- fold for first-degree relatives. HLA 
genes have emerged as strongly associated with an increased susceptibility to SSc. A wide array of 
HLA genes has been linked with SSc across several studies conducted in different populations. 
Various associations between each HLA and autoantibody specificities or organ involvements have 
been reported. Genome wide association studies (GWAS) and candidate-gene studies have revealed 
an association of scleroderma with single nucleotide polymorphisms mapping in the following 
genes: STAT4, IRF3, IRF5, IRF7, IRF8, DNASE1L3
52
, TLR2, CTGF, PTPN22, IL2RA, IL12RB2, 
CD247, PPAR- and caveolin 153.  
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Systemic sclerosis: etiopathogenic features 
The pathogenesis of scleroderma is extremely complex and still not fully elucidated. It is 
characterized by three cardinal pathophysiologic processes, namely vascular dysfunction, 
inflammation and fibrosis. Fibrosis is the hallmark of scleroderma; however, endothelial 
dysfunction and immune cell infiltrates are thought to antedate the development of tissue fibrosis. 
Indeed, in tissue samples from scleroderma patients, rarefaction of capillaries and perivascular 
inflammatory infiltrates were observed to precede fibrotic changes. It is currently not clear which 
event provides the primary insult in scleroderma: different paradigms for SSc pathogenesis have 
been proposed, each envisaging a potential trigger for SSc: endothelial damage, viral infections, 
ECM injury… Surely, the three pathophysiologic processes are disparate, but yet strictly 
interrelated one with the other. The interplay between the pathophysiologic processes in 
scleroderma etiopathogenesis is illustrated in Figure 1.  
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Figure 1. Schematic overview of the interplay between endothelial damage, immune activation 
and fibrosis in scleroderma pathogenesis (Original figure).  
IL: interleukin; TGF-: transforming growth factor –; PPAR-: peroxisome proliferator-activated receptor -; MCP-1: 
monocyte chemotactic protein -1; MMP: matrix metalloproteinase; CTGF: connective tissue growth factor; IFN: 
interferon; VEGF: vascular endothelial growth factor; HIF: hypoxia-inducible factor; ET-1: endothelin-1.  
 
 Vascular dysfunction 
The prominent endothelial dysfunction characteristic of SSc is secondary to a dysregulation of 
vascular tone, with subsequent vascular spasm and decreased blood flow. 
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Endothelial cells have been appointed as the main player in vascular dysfunction. Indeed, the 
above-cited poor control of vascular tone is ascribable to the unbalanced production by endothelial 
cells of vasoconstrictor and vasodilator mediators. In particular, scleroderma endothelial cells have 
been shown to synthetize a markedly lower amount of nitric oxide, the most potent endothelial 
vasodilator agent. Interestingly, transforming growth factor – (TGF- has been reported to inhibit 
the enzyme nitric oxide synthase. The resulting impaired production of nitric oxide was found to 
contribute to platelet activation and to oxidative stress and to promote intimal hyperplasia. In 
addition, an up-regulation of endothelin-1 (ET-1), the most potent vasoconstrictor agent, has been 
reported
54
. In SSc, endothelial cells have been shown to express higher levels of adhesion molecules 
as endothelial-leukocyte adhesion molecule (ELAM) -1, inter-cellular adhesion molecule (ICAM)-1 
and CD34
55
.  
Endothelial cells have been proposed as the first target in SSc: an initial insult to the endothelium 
(cold exposure, viral infection, anti-endothelial antibodies [AECA]) might induce vasoconstriction 
leading to hypoxia, ultimately resulting in tissue fibrosis. Consistently, endothelial cell apoptosis 
has been described early on disease course; on the other hand, there is no evidence from animal 
models that an endothelial injury might result in tissue fibrosis
55
. 
SSc is also characterized by a defective neoangiogenesis, a complex process that requires 
mobilization of endothelial cell progenitor cells (EPCs) and proliferation and differentiation of 
resident cells. Reduced numbers and functionality of circulating CD34
+
 and CD133
+
 EPCs have 
been reported in scleroderma
55
. Neoangiogenesis is regulated by a fine-tuning of pro-angiogenic 
and anti-angiogenic mediators. Surprisingly, the vascular endothelial growth factor (VEGF), a 
potent angiogenic factor, was over-expressed in skin and serum samples from SSc patients; its 
serum levels have been found to correlate with the development of fingertip ulcers. This might be 
explained by the evidence that VEGF exerts a proangiogenic activity when over a concentration 
threshold; below this value, VEGF stimulates the formation of chaotic and instable blood vessels. 
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Similarly, TGF-displays a pro- or anti-angiogenic action depending on its concentration56. 
Vascular rarefaction ultimately results in tissue hypoxia, which leads to the activation of the 
transcription factor hypoxia inducible factor -1 (HIF-1). Besides inducing VEGF expression, HIF-1 
serves as a potent pro-fibrotic stimulus: it induces synthesis of ECM, expression of TGF- and 
connective tissue growth factor (CTGF) and promotes epithelial-mesenchymal transition (EMT)
57
. 
From a clinical point of view, vascular dysfunction results in the reduced density and the irregular 
architecture of the capillary network, leading to a decreased blood flow and subsequent tissue 
hypoxia. Vascular manifestations of SSc comprise Raynaud‟s phenomenon, digital ulcers, PAH and 
SRC. 
 
 Immune activation 
An inflammatory infiltrate with perivascular localization is characteristic of the early phases of 
scleroderma. Such infiltrate consists mainly of CD4+ T cells and macrophages. Consistently, 
elevated levels of monocyte chemoattractant protein (MCP)-1/CCL2, a potent chemoattractant for 
both T cells and monocytes, have been reported in both sera and tissue samples from scleroderma 
subjects
58
. 
 
In scleroderma patients, circulating T cells as well as T cells infiltrating skin or lung tissues display 
a predominant Th2 profile. Th2 polarized response is characterized by the production of cytokines 
as interleukin (IL)-4, IL-5, IL-13, IL-21 and MCP-1/CCL2. These Th2 cytokines have been 
reported to directly favour collagen production by scleroderma fibroblasts and to inhibit matrix 
metalloproteinase (MMP) function; moreover, IL-4 has been reported to enhance fibroblast 
proliferation and to synergize with TGF-. Activated T cells stimulate SSc fibroblasts via 
CD40/CD154, inducing inflammatory mediators. 
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A growing research interest has focused on an additional T cell subset in scleroderma, the Th17 
cells. IL-6, IL-1, IL-23 and TGF- drive the differentiation towards Th17 subset. Th17 cells 
synthetize high amount of IL-17; in turn, IL-17A has been shown to induce IL-6 and IL-8 
production and ICAM-1 expression in human fibroblasts. In endothelial cells, IL-17A enhances 
TGF- production59. The frequency of circulating Th17 cells is markedly raised in SSc60. Increased 
levels of IL-17 and of IL-17 inducing cytokines (IL-1, IL-6, IL-23) have been reported in SSc 
patients
61
.  
 
Macrophages found in SSc skin biopsies appear to be alternatively activated (M2); this lineage of 
macrophages highly expresses several receptors such as hemoglobin scavenger receptor (CD163), 
class A scavenger receptor (CD204) and mannose receptor (CD206). M2 macrophages are activated 
by Th2 cytokines as IL-4 and IL-13. M2 macrophages are thought to play a role in tissue 
remodeling and profibrotic phenotypes, providing an important source of profibrotic cytokines as 
TGF-. The role of macrophages in SSc is further highlighted by the fact that lipopolysaccharide 
(LPS)-mediated pro-inflammatory and pro-fibrotic effects were prevented in a macrophage-
deficient mouse model
62
. To note, M2 macrophages are more numerous in scleroderma skin 
compared to control specimens; SSc patients have been shown to display higher serum soluble 
CD163 levels
63
. 
 
The pathogenic role of B cells in SSc has been progressively recognized. Indeed, in scleroderma 
skin B cell genes have been found to be highly up-regulated
64
, and B cells from patients with 
scleroderma to over-express CD19, resulting in hyper-responsiveness and autoantibody formation
65
. 
Increased levels of B-cell activating factor (BAFF) have been described in in the serum and skin 
samples from SSc subjects, suggesting that BAFF might contribute to B cell abnormal function in 
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SSc
66
. B cells play a pivotal role in SSc-ILD: they are prominent in lymphocytic infiltrates seen in 
lung biopsy specimens from SSc-ILD patients, and ILD progression has been associated with an 
increased percentage of CD19-positive cells in bronchoalveolar lavage fluid
67
. In vitro, circulating 
B cells isolated from scleroderma patients induced IL-6, TGF-1, CCL2 and collagen secretion in 
cocultured dermal fibroblasts; collagen secretion was attenuated by anti-TGF-1 antibody
68
. 
Consistent evidence has been raised in vivo: CD19-deficient mice were resistant to fibrosis after 
bleomycin treatment, while CD19 over-expression exacerbated fibrosis
69
. 
 
The pathophysiologic mechanisms underlying the strong association of scleroderma-specific 
autoantibodies with both scleroderma subsets and the pattern of organ involvement have still to be 
unravelled. Available evidence in support of a direct pathogenic role of each scleroderma-specific 
antibody is hereby discussed.    
Early studies showed that purified human ATA inhibit relaxation of supercoiled DNA. More 
recently, research attention has focused on ATA antigen. Indeed, topoisomerase I has been reported 
to bind to the surface of dermal fibroblast cell lines. Such binding appeared to be dose-dependent 
and saturable, and was mediated by G-protein coupled chemokine receptor (CCR) 7 and heparan 
sulfate proteoglycans
70,71
. Topoisomerase I itself was shown to engage intra-cellular signaling 
pathways with downstream recruitment of C1, c-Raf, ERK-1/2 and p38 MAPK culminating in the 
stimulation of fibroblast migration in an in vivo wound healing assay
71
. In addition, surface-bound 
antigen provided a docking site for ATA: indeed, affinity purified ATA have been demonstrated to 
bind to fibroblasts at flow cytometry, immunofluorescence and confocal microscopy
72
. Moreover, 
ATA amplified topoisomerase I binding to fibroblast surface in a titer-dependent manner. 
Interestingly, binding of ATA to fibroblasts required the presence of topoisomerase I, a nuclear 
enzyme which is released by apoptotic cells. Once bound to the surface of fibroblasts, ATA 
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complexed with topoisomerase I induced adhesion and activation of cocultured monocytes
73
. This 
whole burden of data prompted the authors to envisage that the autoantigen topoisomerase I might 
allow to alert the immune system leading to in situ recruitment of inflammatory cells.  
Researchers from another group observed that scleroderma sera obtained from ATA positive 
patients were shown to induce higher levels of IFN-compared to ACA and antibodies against 
nucleolar proteins in peripheral blood mononuclear cells (PBMCs). Such effect was prevented by 
bafilomycin (an endosomal acidificator), by an antibody against FcReceptor (FcR) II (CD32) and 
by RNA digestion, suggesting that ATA-containing immune complexes induce IFN- via Fc or via 
endosomal Toll-like Receptors (TLRs)
74
.  
 
In early reports, ACA were found to disrupt mitosis. More recently, it was shown that CENP-B 
bound to the surface of contractile pulmonary artery smooth muscle cells, whereas no binding was 
observed to fibroblasts and endothelial cells. Endothelial cells could provide a potential source of 
extracellular antigen: CENP-B from apoptotic endothelial cells was observed to bind to smooth 
muscle cells. In addition, CENP-B was reported to activate intra-cellular signaling cascade through 
the engagement of CCR3. Moreover, CENP-B binding induced a CCR3-epidermal growth factor 
receptor (EGF-R) crosstalk via a MMP-dependent mechanism
75
. CENP-B binding culminated with 
the downstream recruitment of focal adhesion kinase (Fak), Src, ERK-1/2, and p38 MAPK 
pathways. These signaling cascades culminated in the synthesis of IL-6 and IL-8 and in the 
stimulation of the migration of smooth muscle cells
76
. Antibodies against CENP-B were reported to 
prevent EGF-R transactivation and the subsequent secretion of IL-8
75
.   
 
In early studies, ARA were demonstrated to inhibit RNA transcription. Most recently, the striking 
association and the temporal clustering between cancer and scleroderma with ARA positivity has 
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gained attention. In cancer tissues from patients with ARA-positive scleroderma, genetic alterations 
in the PLOR3A locus coding for the enzyme RNA polymerase III were noted, whereas no alteration 
could be detected in tissue samples from patients with ARA-negative SSc. In addition, analyses of 
peripheral blood lymphocytes suggested that the mutant peptide could act as an immunogen and 
induce ARA production in vivo. ARA purified from SSc patients recognized the wild type and the 
mutant form to a similar extent, suggesting that antibody response does not discriminate between 
the two isoforms
77
.    
 
Several other autoantibodies have been described in SSc; however, most are not specific for 
scleroderma, being described in several other CTDs and in healthy subjects.  
Antibodies to fibroblasts (AFA) can be detected in approximately 46-58% of scleroderma sera, with 
a higher prevalence among diffuse compared to limited SSc. In particular, AFA were reported to 
bind to the cell surface of fibroblasts but not of endothelial and smooth muscle cells. In addition, 
AFA can induce a pro-adhesive, pro-fibrotic and pro-inflammatory fibroblast phenotype
78AFA are 
internalized by fibroblasts via a caveolin-linked and Fc-independent pathway
79
. It has been 
suggested that anti-fibroblast activity might be mediated by ATA. Indeed, AFA purified from SSc 
patients strongly reacted with topoisomerase I at ELISA and immunoblotting. Consistently, 
positivity for AFA at high titers has been shown to correlate with pulmonary involvement and 
death
72
. 
AECA can be detected in 25-85% of patients with SSc, but can be found in patients with other 
autoimmune conditions as well. It has been proposed that AECA could mediate endothelial cell 
activation through activation of the caspase 3 pathway, antibody-dependent cell-mediated 
cytotoxicity and endothelial cell apoptosis
80
.  
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Stimulatory autoantibodies against the platelet derived growth factor receptor (PDGF-R) have been 
reported in sera from SSc patients. These antibodies were shown to induce phosphorylation of 
PDGF-R, with up-regulation of -SMA and collagen expression in fibroblasts81. However, 
confirmation of these results in a larger cohort is still warranted. Recently, it has emerged that 
positivity for anti-PDGF-R antibodies is not restricted to SSc, but could also be detected in healthy 
individuals
82-84
. 
Autoantibodies against angiotensin and endothelin receptors (anti-AT1R and anti-ETAR antibodies) 
have been recently described in scleroderma patients, with elevated antibody levels correlating with 
major disease manifestations
85
. These autoantibodies activated human microvascular endothelial 
cells (HMEC), inducing IL-8 and vascular cell adhesion molecule (VCAM) -1. Stimulation of 
HMEC with whole IgG from SSc patients resulted in increased neutrophil migration and collagen 
production
86
.  
Lastly, IgG fractions purified from scleroderma patients have been shown to bind also to vascular 
smooth muscle cells, culminating in the induction of cell contraction
87
 and in a pro-fibrotic 
response, with a greater stimulation of ERK1/2 and Akt phosphorylation compared to control IgG. 
Such effect was mediated by EGF-R but not by PDGF-R
88
. 
 
 Fibrosis 
It was 1972 when Carwile LeRoy observed that scleroderma skin fibroblasts secrete higher amounts 
of collagen compared to healthy control cells
89
. Fibroblasts are currently regarded as the main 
effector cells in scleroderma. Besides their role in ECM deposition, SSc fibroblasts can synthetize 
pro-inflammatory cytokines and chemokines (IL-1, IL-6, IL-8, MCP-1)
90
. Through production of 
chemokines, fibroblasts recruit and stimulate T cells and monocytes, and attract and retain B 
40 
 
lymphocytes. In addition, scleroderma fibroblasts display an altered expression of cell surface 
integrins and receptors for TGF- and platelet-derived growth factor (PDGF)57.  
Scleroderma fibroblasts can differentiate into myofibroblats, contractile -smooth muscle actin (-
SMA) positive cells that secrete high amount of collagen and other ECM components. 
Myofibroblasts physiologically accumulate at wound site in response to tissue injury.  However, in 
scleroderma myofibroblasts remain in situs even once the wound has been repaired, and their 
number is typically expanded
90
. Besides fibroblasts, several other cells -of mesenchymal as well 
non-mesenchymal origin- can differentiate into myofibroblasts: pericytes, fibrocytes, smooth 
muscle, epithelial and endothelial cells (Figure 2). The differentiation of resident and circulating 
cells into myofibroblasts has been appointed as an important mechanism contributing to SSc 
fibrosis. The process where epithelial cells transdifferentiate into mesenchymal cells is referred to 
as EMT
91
. TGF-, Wnt and hypoxia are the most important mediators promoting EMT, whereas 
peroxisome proliferator-activated receptor (PPAR- plays an inhibitory role57.    
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Figure 2. Cells potentially transdifferentiating into myofibroblasts (Original Figure). 
The complex interplay between endothelial damage, immune activation and fibrosis involves 
several mediators, whose role in scleroderma etiopathogenesis is below discussed in details. 
 
o Transforming growth factor - 
 TGF- belongs to the TGF- superfamily, which enlists among the others bone morphogenic 
protein (BPM), nodals and activin. Three TGF- isoforms have been to date identified: TGF-1, 
TGF-2 and TGF-3. The three isoforms share an almost identical structure comprising six cysteine 
residues joined by three disulfide bonds. Several cells synthetize TGF-: fibroblasts, 
megakaryocytes, endothelial cells and T cells, to name some. TGF- is secreted in a biologically 
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inactive molecule, which is sequestered in the extracellular matrix in a latent form. In the ECM, 
TGF- binds to latent TGF- binding protein (LTBP) to form a large latent complex (LLC). Great 
amounts of TGF- are conserved in the connective tissues, providing a reservoir for easily available 
TGF-. In turn, LLC binds to fibronectin and fibrillin, and these matrix interactions play an 
important role in activation of latent TGF-. Indeed, upon injury, TGF- is activated via interaction 
with thrombospondins and integrins. Interestingly, thrombospondin-1 and 5 and 3 integrins 
have been found to be significantly over-expressed in SSc fibroblasts. TGF- activation also 
requires cellular tension: cells with  integrins on the cell membrane can exert traction on latent 
TGF-, thus increasing its activation. Once activated, TGF- binds to a TGF- receptor (TGF--R), 
which is a heterodimer composed of two transmembrane serine/threonine kinase proteins. A TGF-
1 pseudoreceptor, the bone morphogenetic protein and activin membrane-bound inhibitor 
(BAMBI), has also been described. TGF- recruits a Smad-dependent and a Smad-independent 
pathway. Smad2/3 is the main mediator of the Smad-dependent signaling cascade, which 
culminates with collagen transcription. Conversely, Smad7 exerts an inhibitory function
92,93
. 
Through the Smad-independent pathways, TGF- activation leads to the engagement of several 
mediators, as phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, c-Abl (a Src family non-
receptor tyrosine kinase) and Egr-1 (a DNA-binding protein zinc finger transcription factor)
94
. In 
addition, TGF- interaction with integrin results in the phosphorylation of Fak, a non-receptor 
protein tyrosine kinase. Fak is recruited to focal adhesion upon integrin clustering and, when 
phosphorylated, increases its catalytic activity, leading to the activation of PI3K. Thus, Fak 
activation has been reported to lead to myofibroblast differentiation and to the expression of pro-
fibrotic genes via MEKK/JNK pathway
95
.  
TGF- is the most potent pro-fibrotic mediator in scleroderma pathogenesis. It favours the secretion 
of collagen and other components of the ECM, such as fibronectin and thrombospondin-1. TGF- 
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has also been shown to induce several secondary mediators such as CTGF, platelet-derived growth 
factor (PDGF) and PDGF-R, plasminogen activator inhibitor (PAI) -1 and cartilage oligomeric 
matrix protein (COMP). In addition, TGF-stimulates cell differentiation into myofibroblasts in the 
context of EMT. TGF also exerts multiple effects on endothelial cells: it was reported to up-
regulate the expression of VEGF, ET-1, endothelial nitric oxide synthase and to down-regulate the 
vasodilator inducible nitric oxide synthase, MMP-1 and tumour suppressor, phosphatase and tensin 
homolog (PTEN)
93
. PTEN encodes a lipid phosphatase, which inhibits the PI3K/Akt signaling 
pathway. In addition, PTEN acts as cofactor for Smad3 phosphatase, with subsequent inhibition of 
Smads
96
.  
Unfortunately, the large reservoir of latent TGF- prevents the evaluation of TGF- in vivo. Indeed, 
TGF- mRNA levels were reported to be elevated in skin samples from diffuse patients; however, 
serum active TGF-1 was reduced in patients with dcSSc and inversely correlated with mRSS
97
. At 
microarray analysis, a TGF--responsive signature was demonstrated in a subset of patients with 
dcSSc
98
.  
 
o Connective tissue growth factor  
CTGF (also known as CCN2) is a 36 to 38 kDa cysteine-rich peptide containing 349 amino acids 
which belongs to the CCN family of growth factors. It is expressed in endothelial cells, fibroblasts, 
chondrocytes and smooth muscle cells.  CTGF is induced by TGF-, but also by PDGF, EGF and 
fibroblast growth factor (FGF). It has been shown to modulate fibroblast cell growth and ECM 
secretion, being required for TGF- mediated effects. In particular, CTGF was required for the 
activation of Smad1 and Smad3, even though on its own CTGF could not trigger collagen 
expression. It is plausible that both CCN2 and TGF-, bound to each other, are necessary for 
activation of Smad1/Erk1/2 signaling cascade
99
.  
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o Endothelin-1 
ET-1 is a 21-amino acid peptide, which provides the predominant of the three human isoforms. ET-
1 binds to two G protein receptors, named ETAR and ETBR. ET-1 is produced mainly by endothelial 
cells, but also by fibroblasts and smooth muscle cells. ET-1 is a vasoactive peptide: it mediates 
vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the 
cardiovascular system. It activates adhesion molecules as ICAM-1 on endothelial cells and 
stimulates smooth muscle cell vasoconstriction. In addition, ET-1 increases the production of 
collagen and fibronectin by fibroblasts, and down-regulates MMP-1 expression
100
. The pro-fibrotic 
effects are mediated by a wide array of pro-fibrotic mediators: indeed, ET-1 has been shown to 
induce TGF-β and CTGF via ERK. It enhances the conversion to myofibroblasts, with the up-
regulation of -SMA mediated by ETAR and the Akt/PI3K/rac signaling pathway
101
. In turn, TGF- 
has been shown to induce ET-1 expression through a Smad-independent pathway involving JNK. 
Mice over-expressing ET-1 display progressive lung fibrosis, vascular dysregulation, remodeling, 
and increased macrophage infiltration of tissue and markers of vascular activation
102
. Consistently, 
ET-1 has been reported to be over-expressed in SSc skin, lung, and kidney; its serum levels were 
increased in the sera of scleroderma patients. 
 
o Interleukin-6 
IL-6 is a pleiotropic proinflammatory cytokine produced by lymphocytes, fibroblasts and 
monocytes. Its physiologic functions include regulation of cellular proliferation, activation and 
differentiation of different cell types. The expression of IL-6 receptor (IL-6R) is restricted to 
hepatocytes and leucocytes; however, IL-6 can stimulate cells not expressing IL-6R via the soluble 
receptor (sIL-6R). Engagement of IL-6R leads to cell proliferation and mitogenesis. Cell 
stimulation through sIL-6R is named trans-signaling, which activates an intra-cellular transduction 
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cascade through Jak, STAT and MAPK. Scleroderma dermal fibroblasts produce higher levels of 
IL-6 compared to cells obtained from healthy controls. In in vitro fibroblast coltures, IL-6 trans-
signaling elicited a potent pro-fibrotic effects with enhanced synthesis of collagen, -SMA and 
CTGF; these effects were mediated by JAK2/STAT3 and Erk pathways
103
. In fibroblasts from IL-6 
knockout mice, IL-6 induced -SMA expression via JAK1 kinase104. IL-6 serum levels have been 
shown to be increased among SSc patients compared to controls, in particular in those with early 
dcSSc
103,105,106
. IL-6 serum levels have been found to correlate with thrombocytosis and acute phase 
reactants and to be associated with severe cutaneous involvement and poor long-term survival. 
Expression of IL-6 in the skin is prominent in patients with early diffuse disease; at 
immunostaining, IL-6 expression appeared to be localized to dermal fibroblasts, mononuclear cells 
and endothelial cells
103
. 
 
o Interleukin-8  
IL-8 is a CXC chemokine that acts as a chemoattractant factor for neutrophils. IL-8 and its receptors 
CXCR1 and CXCR2 play a central role in regulating angiogenesis by enhancing proliferation and 
survival and inhibiting apoptosis of endothelial cells expressing CXCR1 and CXCR2
107
. IL-8 is 
produced by endothelial and epithelial cells as well as by scleroderma fibroblasts and macrophages. 
IL-8 has been found to stimulate the production of MMPs; its secretion is induced by hypoxic 
stimuli via NFB. Dermal fibroblasts obtained from SSc patients were reported to secrete higher 
quantities of IL-8 compared to cells from healthy controls. IL-8 levels have been found to be 
increased in skin samples from SSc subjects, in particular in those patients with early disease
108
. 
SSc patients present higher –even though not significantly- IL-8 serum levels compared to healthy 
subjects
106
. Three polymorphisms in IL-8 gene have been associated with the development of 
fibrosing alveolitis among SSc patients
109
.  
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o Matrix metalloproteinases 
MMPs are a family of at least 23 calcium-activated and zinc-dependent enzymes; their activity is 
inhibited by the tissue inhibitors of metalloproteinases (TIMP). These endopeptidases are deputed 
to the degradation of ECM components; they also favor neovascularization as are implicated in the 
degradation of vessel basal membrane. The expression of MMPs can be induced by several 
mediators: IL-1, IL-12, EGF, PDGF and TNF, while TGF-down-regulates their levels. Dermal 
fibroblasts from SSc subjects have been observed to produce higher amounts of MMP-9 and MMP-
12 compared to cells from healthy controls in response to IL-1 and tumour necrosis factor (TNF) -
110 In scleroderma patients, levels of MMP-9, MMP-7 and MMP-12 have been found to be raised, 
in particular among those with diffuse disease
111-113
, whereas TIMP-1 levels were decreased. The 
subsequent disequilibrium between MMPs and TIMP-1 in scleroderma is believed to promote the 
accumulation of ECM
114
. 
 
o Interferon 
Interferons (IFNs) provide a heterogeneous family of cytokines originally identified as inductors of 
resistance to viral infections. Type I IFNs enlist IFN-, IFN- and IFN-ω. IFN- and – share the 
same structure, cellular receptors and biologic effects, such as anti-viral, anti-proliferative and 
immune modulatory functions
63
. In particular, IFN has been demonstrated to enhance B cell 
response by inducing autoantibody production in patients; it also contributes to T cell priming
115
. It 
has recently emerged that IFNs might exert an anti-fibrotic effect. IFN-γ suppresses collagen 
transcription through recruitment of collagen transcription start site of a multiprotein repressor 
complex containing PPAR-γ, class II trans-activator (CIIA) and regulatory factor for X-box 5 
(RFX5). In cultured human dermal fibroblasts IFN attenuated CTGF and collagen up-regulation 
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by TGF-116. Moreover, in fibroblasts incubation with IFN-abrogated collagen and -SMA 
expression
117
. 
There is an increasing evidence of an “interferon signature” in SSc, similarly to what reported in 
other autoimmune diseases, such as systemic lupus erythematosus. IFN-α as well as IFN-regulated 
genes have been described as increased in SSc dermis, with an over-expression of allograft 
inflammatory factor -1 (AIF-1), an IFN- inducible gene. The IFN-regulated gene expression in the 
skin was found to correlate with mRSS. In addition, peripheral blood cells and PBMCs from SSc 
patients were reported to express increased levels of IFN-regulated genes 
118
. Circulating monocytes 
and tissue macrophages from scleroderma patients were reported to highly express the sialoadhesin 
Siglec-1, an IFN-induced gene. In addition, upon stimulation with sera from SSc patients and 
necrotic cell material, healthy PBMCs and purified plasmacytoid dendritic cells produced increased 
amounts of IFN-. IFN- production by stimulated dendritic cells was decreased by antibodies 
against FcRII or by chloroquine: IFN- production by plasmacytoid dendritic cells might then be 
modulated by immune complexes containing RNA via a FCRII-dependent and endosome-
dependent pathway.  Sera with ACA or ATA induced low levels of IFN-, whereas sera with 
multiple autoantibodies to RNP and/or SSA induced high levels of IFN-119. In particular, ATA-
positive sera were shown to induce higher levels of IFN-compared to ACA and antibodies against 
nucleolar proteins
74
.  
It has been proposed that activation of the innate immune receptors TLRs might account for the 
increased levels of IFN in SSc
57
. Consistently, agonists of TLR3, TLR7 and TLR9 – but not TLR2 
and TLR4 ligands- were reported to induce Siglec-1 expression in dermal fibroblasts
120
. In turn, 
type I IFNs were shown to up-regulate TLR3 in dermal fibroblasts, and such IFN-induced increase 
in TLR3 expression was augmented by TGF-coincubation116. 
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o Peroxisome proliferator-activated receptor  
PPAR-γ belongs to the nuclear hormone receptor superfamily; it acts as a ligand-activated intra-
cellular transcription factor providing a master regulator of glucose and lipid homeostasis. PPAR-γ 
is targeted by the insulin-sensitizing drugs thiazolidinediones, while rosiglitazone is a potent PPAR-
γ agonist. PPAR- is increasingly recognized as a regulator of connective tissue homeostasis, since 
it exerts potent anti-fibrotic effects. Consistently, PPAR-expression was inhibited by several pro-
fibrotic mediators: TGF-, Wnt and CTGF57. It has been shown to antagonize TGF- effects: 
indeed, PPAR- inhibited TGF- induced myofibroblast activation and abrogated TGF- induced 
collagen production. In particular, TGF- was reported to attenuate Smad-3 mediated response. 
This activity is mediated by the inhibition of Fak, a kinase involved in the activation of Akt. Thus, 
inhibition of Fak by PPAR- results in the inhibition of PI3K/Akt pathway121. Moreover, PPAR-
can modulate EMT, providing the most potent negative regulator57. The role for PPAR-γ as an 
effective inhibitor of dermal fibrosis has been confirmed in the bleomycin-induced mouse model of 
SSc. Administration of rosiglitazone significantly diminished inflammation and fibrosis, with 
reduced monocyte infiltration and prevention of collagen up-regulation and myofibroblast 
accumulation
122
.  Consistently, triterpenoid, a PPAR- agonist, was recently proved to ameliorate 
fibrosis in two animal models of scleroderma by abrogating TGF- Smad-dependent and Akt 
signaling pathways
123
. In lesional tissue samples from scleroderma patients, PPAR- expression was 
impaired, being inversely correlated with TGF- activity. 
 
o Wnt/-catenin  
Wnts are a family of 19 secreted signaling glycoproteins playing a key role in embryonic 
development and organogenesis. Wnt signaling is mainly mediated by the canonical -catenin 
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pathway.  In the absence of Wnt ligand, cellular -catenin is phosphorylated and then ubiquitinated 
undergoing proteasomal degradation. Upon binding of Wnt ligand to Frizzled (FZD) cell surface 
receptors, catenin is stabilized, accumulates in the cytosol and translocates into the nucleus 
where it interacts with DNA-binding factors such as TCF/LEF thus regulating the transcription of 
several target genes. The canonical Wnt pathway has been shown to stimulate fibroblast activation; 
a cross-talk between Wnt and TGF- signaling pathways has also been identified. TGF- has been 
shown to increase the responsiveness of scleroderma fibroblasts to Wnt proteins; in turn, Wnt3a 
induced TGF-1 with phosphorylation of Smad2 and Smad3. In addition, Wnt signaling cascade 
was proved to induce adipocyte and mesenchymal progenitor cell differentiation in vitro. In vivo the 
transgenic Wnt expression has been demonstrated to induce a scleroderma-like skin fibrosis in the 
mouse
124
. A constitutive activation of Wnt--catenin cascade has been reported using skin and lung 
specimens from patients with SSc-associated pulmonary fibrosis. The source of Wnt ligand in SSc 
are unknown, but gene-expression profiling of scleroderma skin has demonstrated an over-
expression of Wnt ligands and -catenin regulated genes125.  
 
o PI3K/Akt/mTOR 
Akt activity has been shown to be increased in scleroderma fibroblasts; PI3K/Akt signaling has 
been implicated in collagen production and cell proliferation. Akt activation can lead to the 
recruitment of the mammalian target of rapamycin (mTOR). mTOR is a 289-kDa serine-threonine 
kinase that regulates cell functionality; its expression can be modulated by TGF- in dermal 
fibroblasts from healthy controls
126
. mTOR has been shown to positively regulate collagen 
production in dermal fibroblasts via a PI3K-independent pathway. Interestingly, in human oral 
keratinocytes mTOR has been shown to modulate the expression of pro-inflammatory cytokines 
induced by Poly(I:C), the TLR3 agonist
127
. Its role in mediating fibrosis has been demonstrated 
using the bleomycin-induced and the tight-skin scleroderma mouse models. Rapamycin, a mTOR 
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inhibitor, was proved to reduce skin fibrosis in both models, attenuating the production of IL-4, IL-
6 and TGF-1
128
. In another study, vertical inhibition of PI3K/Akt/mTOR pathway resulted in a 
protective effect against skin fibrosis in two animal models
126
. 
 
o PTEN 
PTEN is a phosphatase whose main substrate is provided by PI3K, the Akt activator. PTEN 
expression is suppressed by TGF- and is stimulated by PPAR-. In vitro, PTEN-deficient 
fibroblasts were reported to over-express collagen and CTGF, an effect that was mediated by 
Akt/PI3K. In vivo, PTEN deletion appeared to be sufficient to induce fibrogenesis. PTEN 
expression has been described as reduced in skin fibroblasts from subjects with diffuse disease
96
.  
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The interplay between PI3K, Akt, mTOR, Fak and PTEN is schematically presented in Figure 3.   
 
 
Figure 3. Schematical representation of the interplay between TLR, PI3K, Akt, mTOR, Fak 
and PTEN (Original figure). 
TLR: Toll-like Receptor; TRIF: TIR-domain containing adaptor-inducing interferon; PI3K: phosphatidylinositide 3-
kinases; mTOR: mammalian target of rapamycin; PTEN: tumour suppressor, phosphatase and tensin homolog; PPAR-: 
Peroxisome proliferator-activated receptor-; Fak: focal adhesion kinase. 
 
o Toll-like Receptors 
TLRs are a family of highly conserved pattern recognition receptors (PRR), which play a critical 
role in innate immunity, They are crucial in sensing pathogen-associated molecular patterns 
(PAMPs) of both microbial and viral origins; they also binds endogenous damage associated 
molecular patterns (DAMPs), which are produced upon cellular stress or mechanical trauma and act 
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as danger signals
129
. TLRs are trans membrane proteins consisting of three main domains: i) a 
leucin-rich repeat (LRR) extracellular domain; ii) a trans-membrane domain and iii) a cytoplasmic 
horseshoe-like TIR (Toll-IL-1R resistance) domain. In human, ten TLRs (TLR1 to TLR10) have 
been described; the respective ligands are detailed in Table 1. 
 
TLR Exogenous ligands Endogenous ligands Synthetic ligands 
TLR1 Bacterial triacylated lipoproteins   
TLR2 
Bacterial peptidoglycan and 
lipoproteins, zymogen yeast particles 
HMGB-1, hsp60, hsp70 and hsp90, 
serum amyloid 
LPS 
TLR3 Viral dsRNA  Poly(I:C) 
TLR4 Gram-negative bacterial LPS 
Hyaluronan fragments, HMGB-1, 
hsp-20, hsp60, hsp70, hsp96, 
Fibrinogen, Extra domain A of 
fibronectin, Tenascin C, Surfactant 
protein-A 
LPS 
TLR5 Bacterial flagellins   
TLR6 
Lipotechoic acid, yeast zymosan 
particles 
Soluble tuberculosis factor, porins, 
hsp60, hsp70, hsp96, MALP-2 
 
TLR7 Viral ssRNA ICs containing self RNA 
R-848, Bropirimine,  
Imidazoquinoline 
TLR8 Viral ssRNA ICs containing self RNA Imidazoquinoline 
TLR9 
Unmethylated viral and bacterial 
CpG DNA 
ICs containing self DNA CpG ODN 
TLR10 Unknown Unknown  
 
Table 1. Exogenous, endogenous and synthetic ligands of human Toll-like Receptors. 
TLR: Toll-like receptors; ICs: immune complexes; hsp: heath shock protein; ss: single stranded; ds: double stranded. 
 
TLRs are widely expressed by many immune and non-immune cells, such as fibroblasts, epithelial 
and endothelial cells
130
.  Some TLRs – such as TLR2, TLR4, TLR5 and TLR6- are expressed on the 
53 
 
cell surface. Other TLRs display an intra-cellular localization: lysosomal or endosomal 
compartments and the endoplasmic reticulum; this is the case of TLR3, TLR7, TLR8 and TLR9. 
TLRs form hetero- or homo-dimers which are thought to facilitate dimerization to engage intra-
cellular signaling
131
. Upon engagement by ligands, TLR activation results in the production of pro-
inflammatory mediators. All TLRs but TLR3 recruit as cytoplasmatic adaptor protein the myeloid 
differentiation primary response gene (88) (MyD88) and serine/threonine kinases of the IL-1R-
associated kinase family. This pathway culminates with NFB translocation into the nucleus and 
the transcription of various pro-inflammatory cytokines. TLR3 and TLR4 recruit a MyD88-
independent pathway with TIR-domain containing adaptor-inducing interferon (TRIF) as adaptor 
protein. This signaling cascade ultimately leads to the induction of type I IFNs and IFN-inducible 
gene production. In particular, type I IFN production is mediated by two tumour necrosis factor –
receptor-associated factor (TRAF) proteins, downstream of TRIF: TRAF3 and TRAF6. The most 
critically role is played by TRAF3: it activates interferon regulatory factor (IRF) 3, which in turn 
leads to the expression of IFN-. Conversely, IFN- production is mainly induced by TLR7 and 
TLR9 and does not require TRIF but MyD88 and IRF7
129
.  
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The intra-cellular signaling mediators engaged by TLRs are presented in Figure 4.  
 
 
Figure 4. Intra-cellular signaling pathways engaged upon TLR activation. (original figure)  
TRIF: TIR-domain containing adapter-inducing interferon; TIRAP: Toll/interleukin-1 receptor- domain containing 
adaptor protein; MyD88: myeloid differentiation primary response gene (88); IRAK: interleukin-1-receptor-associated 
kinase; TRAF: tumour necrosis factor –receptor-associated factor; IRF: interferon regulatory factor.  
 
TLR involvement in scleroderma is suggested by a consistent burden of experimental data
132
. In 
monocytes from scleroderma patients, a MyD88 inhibitor prevented the up-regulation of TIMP 
mediated by scleroderma sera
133
. Dendritic cells from patients with early SSc responded to TLR2, 
TLR3 and TLR4 ligands with the secretion of higher levels of IL-6, IL-10 and TNF- compared to 
dendritic cells from patients with late disease and healthy controls. It has been proposed that the 
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altered activation of dendritic cells in SSc subjects might lead to a Th2-skewed T-cell activation 
which might in turn induce the production of fibrogenic T cell cytokines
134
.  
To date, most of available evidence points towards TLR3 and TLR4 involvement in SSc 
pathogenesis. 
TLR3 binds to dsRNA oligonucleotides of at least 45 bp in length, which is the minimal length 
required for signal transduction
135
. Polyinosinic:polycytidylic acid [Poly(I:C)], a synthetic analogue 
of double stranded RNA (dsRNA), is the synthetic TLR3 agonist. TLR3 expression in dermal 
fibroblasts was demonstrated to be increased, resulting in a raise in IL-6 and MCP-1 synthesis upon 
incubation with Poly(I:C). TGF-pretreatment augmented TLR up-regulation induced by IFN- 
In skin fibroblasts obtained from SSc patients, Poly(I:C) was shown to induce an IFN- signature 
and to up-regulate TGF-responsive genes (COMP and PAI-1)136. In primary human dermal 
microvascular endothelial cells, human pulmonary endothelial cells and human dermal fibroblasts, 
Poly(I:C) was the only TLR agonist to induce ET-1 and MX2 (an IFN-regulated gene) mRNA 
expression, whereas both TLR3 and LPS up-regulated ICAM-1. Stimulating cells with ligands of 
TLR2, TLR7, TLR8 and TLR9 elicited no effect
137
. Most recently, Fang and colleagues confirmed 
that stimulation with Poly(I:C) pursued in skin and lung fibroblasts the synthesis of IFN- as well 
as an IFN-induced gene expression signature. However, they evinced that Poly(I:C) treatment 
elicited an anti-fibrotic response. Indeed, this dsRNA analogue induced a marked deregulation in 
the expression of collagen, ECM molecules (fibrillin 2, laminin, periostin) and -SMA, with a 
dramatic increase in pro-inflammatory cytokines (IL-6, IL-8, chemokines) and in IFN- –but not 
IFN-- mRNA levels117. In addition, Poly(I:C) abrogated TGF- modulated response; these effects 
were attributable to the disruption of canonical Smad signaling, with the attenuation of TGF- 
induced phosphorylation of Smad3 via the up-regulation of Smad7, an endogenous Smad inhibitor. 
Notably, these effects appeared to be not mediated by TLR3 but by two Poly(I:C) cytosolic 
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receptors, namely the cytosolic RNA helicase retinoic acid inducible gene 1 (RIG-1) and the 
melanoma differentiation-associated gene 5 (MDA5)
117
. Cytoplasmic dsRNA receptors enlist 
dsRNA-dependent protein kinase R (PKR), TNA helicases, RIG-1 and MDA5. 
In vivo, chronic Poly(I:C) infusion resulted in the development of a scleroderma-like disease with 
up-regulation of ET-1, ICAM-1 and IFN- and TGF--modulated genes. The induction of IFN- and 
TGF--induced genes was partially attenuated by TRIF deletion, suggesting that additional 
Poly(I:C) receptors other than TLR3 might be implicated
136,137
. In TICAM1
-/-
 mice, Poly(I: C) 
failed to induce ET-1 but not ICAM-1, suggesting that the latter mediator might be regulated by 
TLR3-independent mechanisms
137
. 
TLR3 expression can be detected in both lesional and non lesional scleroderma skin 
specimens
116,136
. 
 
In monocytes isolated from patients with SSc-ILD, LPS – TLR4 agonist- was shown to induce a 
pro-fibrotic phenotype and to enhance differentiation into fibrocytes
138,139
. Healthy fibroblasts 
stimulated with LPS presented an increased expression of genes involved in ECM synthesis 
(multiple collagens) and fibrogenesis (plasminogen activator inhibitor-1, Wnt2, Wnt5a, CTGF, 
insulin-like growth factor binding protein 3), whereas the effect on pro-inflammatory genes is 
modest. Furthermore, TLR4 was shown to synergize with TGF- in stimulating the synthesis of 
collagen, an effect that was mediated by a decrease in BAMBI, the TGF-1 pseudoreceptor. To 
note, incubation with LPS induced a marked reduction in the levels of miRNA29a, which is a 
negative regulator of collagen expression that is down-regulated in scleroderma fibroblasts
140
.  
The pivotal role played by TLR4 in the pathogenesis of scleroderma has been recently confirmed in 
vivo. TLR4-mutant C3H/HeJ mice were protected from the development of bleomycin-induced skin 
fibrosis, despite an important accumulation of endogenous ligands
140
. In wild type mice chronically 
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receiving LPS by a subcutaneous osmotic pump, a marked up-regulation of pro-inflammatory 
cytokines (IL-1, IL-6, TNF-) and pro-fibrotic TGF- regulated (PAI-1, TIMP, SPP1, collagen 
type 5, MMP-3, MMP-13, thrombospondin) genes was observed at one week. A less striking 
increase in pro-inflammatory mediators was reported after four weeks of LPS stimulation. In both 
TLR4- and MyD88-deficient mouse models, pro-inflammatory and pro-fibrotic effects elicited by 
chronic LPS stimulus were abrogated. In addition, exposure to LPS induced activation of 
macrophages, of both M1 and M2 phenotypes; macrophage recruitment was not reported in TLR4- 
and MyD88-deficient mice treated with LPS
62
.  
In two other mouse models of scleroderma (bleomycin induced fibrosis model and tight skin mice 
model), the abrogation of TLR4 resulted in an attenuation of dermal and lung fibrosis. In 
bleomycin-treated TLR4
-/- 
mice, inflammatory cell infiltrates and neovascularization could not be 
detected. Upon bleomycin treatment, TLR4 knock out attenuated the production of IL-6, the levels 
of total serum IgG and ATA, B cell activation and the Th2/Th17 polarization
141
.  
The expression of TLR4 and its coreceptors CD14 and MD2 resulted to be markedly elevated 
compared to controls in both lesional skin and lungs obtained from scleroderma subjects, as well as 
in explanted fibroblasts. In particular, immunostaining of skin specimens revealed TLR4 expression 
by -SMA positive myofibroblasts and microvascular endothelial cells62.  
 
Given the role played by TLR4, it has been proposed that upon injury several DAMPs might be 
produced. These molecules might induce TLR4 engagement, which in turns leads to the 
uncontrolled synthesis of ECM components. Indeed, besides LPS, TLR4 recognizes several 
endogenous ligands. In scleroderma, potential TLR4 ligands include three categories of molecules: 
i) matrix-derived molecules (hyaluronan, tenascin, byglican, alternatively spliced fibronectin 
extradomain [Fn-EDA]) ii) cellular stress proteins (Hsp60, Hsp70, HMGB1) iii) nucleic acids 
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released from apoptotic or necrotic cells, immune complexes
57
. Several endogenous ligands have 
been evaluated in scleroderma patients. Hsp70 serum levels were found to be increased in 
scleroderma patients compared to controls
142
. HMGB-1 is a 215-aminoacid soluble protein 
composed of two DNA binding binding domains; upon injury or inflammation, it is released in the 
extracellular space and it interacts with TLR2 and TLR4 and the soluble receptor RAGE. SSc 
patients were reported to have higher HMGB-1 serum levels compared to healthy controls; in 
addition, serum HMGB-1 correlated with skin score
143
. In scleroderma bioptic specimens, Fn-EDA, 
tenascin C and hyaluronan were all over-expressed. S100A8/A9 is an additional endogenous ligand 
for TLR4 since it acts as an alarmin. Interestingly, S100A8/A9 serum levels have been 
demonstrated to be markedly elevated in scleroderma patients compared to controls
144
.  
The TLR8 agonist ssRNA40 induced the secretion of TIMP in scleroderma monocytes
133
.  
In skin fibroblasts from healthy controls, the stimulation with TLR7 and TLR9 agonists induced 
IFN-regulated genes. Among the candidate ligands for TLR7 and TLR9, there is Epstein-Barr virus 
(EBV). Indeed, it has been shown to persistently infect scleroderma fibroblasts cultured in vitro. In 
addition, EBV was able to induce a pro-fibrotic phenotype in SSc fibroblasts and to up-regulate 
both TLR7 and TLR9 mRNA expression
145
.  
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Aim of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
Scleroderma autoantibodies are highly disease-specific, being rarely detected in healthy subjects or 
disease controls. In particular, serum antibodies reacting against SSc antigenic targets have been 
shown to precede disease onset, suggesting that they are not a mere reflection of disease process. 
Noteworthy, autoantibody positivity provides not only a strong harbinger of SSc diagnosis, but also 
predicts disease subset and the pattern of visceral involvement. Interestingly, antibody titers have 
been found to correlate with disease activity and mortality. Despite the precise diagnostic accuracy 
and the strong prognostic role played by scleroderma-specific autoantibodies, scarce evidence has 
to date been raised in support of their pathogenic potential. 
The pathogenicity of scleroderma-specific autoantibodies is further suggested by some of their 
immunoglobulinic features: as pathogenic antibodies, they target highly specific and conserved 
functional domains, and are synthesized at high titers upon an antigen-driven and T cell-dependent 
response. In addition, SSc autoantibodies undergo IgM to IgG isotype switch and maturation, 
leading to high affinity IgG that go through intra-molecular and inter-molecular epitope 
spreading
146
. 
The working hypothesis of this study envisaged that immune complexes (ICs) containing 
scleroderma specific autoantibodies -rather than the mere antibody- might be able to elicit a pro-
inflammatory and pro-fibrotic signaling cascade in target cells, thus contributing to SSc 
multifaceted etiopathogenesis. To test this innovative hypothesis, this study evaluated the effects 
elicited by scleroderma IC incubation on skin fibroblasts and endothelial cells obtained from 
healthy subjects. These cells, two key effectors in SSc etiopathogenesis, were used to reproduce in 
vitro the induction phase of the disease.  
Since scleroderma autoantibodies bind –either directly or via bridge proteins- to nucleic acids, it 
was also postulated that the effects induced by ICs from SSc patients bearing different antigenic 
specificities might be mediated by TLRs. To test such hypothesis, cell response to IC stimulation 
was investigated in tlr3-silenced fibroblasts.  
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As a whole, the results emerging from this study might allow to shed light into the pathogenic role 
of scleroderma-associated autoantibodies, an insight that would revolutionize our understanding of 
scleroderma etiology potentially affecting the clinical approach to the disease.  
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Materials and Methods 
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 Patients and healthy donors 
Four patients with a diagnosis of SSc fulfilling 2013 ACR/EULAR criteria were included in this 
study
7
. Patients were selected upon the autoantibody profile: in particular, one patient carried ATA, 
one subject harboured ACA, one patient presented ARA and another one displayed anti-Th/To 
antibodies. Two patients were diagnosed with dcSSc whereas the two other subjects presented a 
limited involvement according to LeRoy
8
. All subjects were female. The median age was of 58 
years (interquartile range [IQR] 52-64). Median disease duration from the onset of first non-
Raynaud‟s phenomenon symptom and inclusion in the study was 119 months (IQR 48-190). 
Serological and clinical features of the recruited scleroderma patients are summarized in Table 2. 
None of the patients presented severe gastrointestinal involvement nor SRC.  
 
 
ANA ENA mRSS RP ILD PAH 
Heart 
Involvement 
Patient 1 + ATA 26/51 + +  + 
Patient 2 + ACA 7/51 +  +  
Patient 3 + ARA 30/51 +    
Patient 4 + anti-Th/To 9/51 + + +  
 
Table 2. Serological and clinical features of the recruited scleroderma patients.  
ANA: anti-nuclear antibodies; ENA: antibodies against extractable nuclear antigens; ATA: anti-DNA topoisomerase I 
antibodies; ACA: anti-centromere antibodies; anti-Th/To: antibodies against Th/To; mRSS: modified Rodnan skin 
score; RP: Raynaud‟s phenomenon; ILD: interstitial lung disease; PAH: pulmonary artery hypertension. 
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Twelve healthy subjects were also enrolled. Healthy subjects had no history of autoimmune disease; 
the detection of serum autoantibodies tested negative in all cases.   
  
 Blood withdrawal 
Blood was withdrawn from 4 scleroderma patients and 2 healthy subjects. Serum samples were 
stored as frozen aliquots at -20°C.  
 
 Autoantibody profile 
Antibodies against nuclear antigens (ANA) were detected by indirect immunofluorescence on 
human epithelial type 2 (HEp-2) cells. Antibodies targeting extractable nuclear antigens (ENA) 
were detected using the commercial kit “EUROLINE - SSc profile” (Euroimmun, Lubeck, 
Germany). This is a qualitative in vitro immunoassay where membrane strips are coated with thin 
parallel lines of purified antigens. In particular, the SSc profile include 12 autoantigens: DNA 
topoisomerase I, CENP-A, CENP-B, RNA polymerase III, U3RNP (fibrillarin), NOR90, Th/To, 
PM/Scl, Ku, Ro52, PDGF-R (Figure 5).   
 
Figure 5. Scleroderma-specific antigens included in the “EUROLINE - SSc profile” 
(Euroimmun, Lubeck, Germany) (from: www.euroimmun.com). 
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 Punch skin biopsy 
Punch skin biopsy specimens were obtained from 10 healthy donors. All subjects provided written 
consent to the procedure. Ethics committee approval for skin biopsy procedure was obtained at 
Istituto Ortopedico Gaetano Pini, Milan, Italy.   
Punch skin biopsy was performed on the dorsal surface of the proximal forearm. The cutaneous area 
to be biopsied was cleansed with povidone-iodine solution, and then anaesthetized with 2% 
lidocaine. A disposable 4-mm skin biopsy puncher (Stiefel Laboratories Inc, Research Triangle 
Park, NC, USA) was used to perform the biopsy (Figure 6). The bioptic specimen was then 
wrapped in sterile gauzes moistened with physiological saline solution and processed within 3 
hours.  
     
 Figure 6. A disposable 4-mm skin biopsy puncher (Stiefel Laboratories Inc, NC, USA) (from: 
www.stiefel.com). 
 
 Isolation of primary skin fibroblasts  
Human dermal fibroblasts were isolated from 4 mm punch skin biopsies obtained from healthy 
subjects
147
. The skin biopsies were put in a 6-cm sterile Petri dish (Corning Incorporated, Corning, 
68 
 
NY, USA), the adipose tissue was removed and the dermal layer was dissected by the means of a 
sterile needle and a skalpel. The specimens were then minced into small chops, these fragments 
were then transferred into a 15-ml tube (VWR International, Radnor, PA, USA) containing a sterile 
solution of 1 mg/ml type I collagenase (Sigma-Aldrich, St. Louis, Missouri, USA) in Dulbecco‟s 
modified Eagle‟s medium (D-MEM, Gibco-Life Technologies, Gronigen, Netherlands). The bioptic 
samples were incubated for 2 hours at 37°C in a CO2 incubator (Heracell 150i, Thermo Scientific 
Vantaa, Finland).  
After a centrifugation at 1200 rpm for 10 minutes, pellets were washed twice with Dulbecco‟s 
phosphate buffered saline (D-PBS, Sigma-Aldrich) and then resuspended in 1 ml D-MEM (Gibco-
Life Technologies) supplemented with 20% fetal bovine serum (FBS, previously decomplemented 
at 56°C, PAA Laboratories-GE Healthcare, Buckinghamshire, UK), 2 mM glutamine (Sigma-
Aldrich), 5000 U/ml penicillin and 500 g/ml of streptomycin (Sigma-Aldrich). The resuspended 
pellets were then transferred into a 25 cm
2
 flask (T25, Corning Incorporated) by a sterile pipette. 
Cultures were maintained at 37°C in a 5% CO2 humidified incubator. The day after, 1 ml of fresh 
culture medium was added. After approximately two weeks, fibroblasts were observed to migrate 
from the skin fragments to T25 surface. When cells reached confluence, non-adherent cells and 
dermal tissue were then removed by washing and the established fibroblasts were passaged with a 
0.25% trypsin/ethylenediaminetetraacetic acid (EDTA) (Gibco-Life Technologies).  
 
 Fibroblast cell culture 
Fibroblast cultures were maintained in D-MEM with 10% FBS, 2 mM glutamine, penicillin (100 
U/ml) - streptomycin (100 g/ml). Passages 4 to 8 skin fibroblasts were used for experiments. 
Confluent fibroblasts were passaged with a 0.25% trypsin/EDTA (Gibco-Life Technologies). 
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 Isolation of primary human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVEC) were isolated from normal term umbilical cord 
vein by type 2 collagenase perfusion (Worthington, Lakewood, NJ, USA)
148
. Briefly, the cord was 
laid on a sterile pad under flow hood, excess blood was removed. A fresh cut with sterile scissors 
was performed on one end of the cord. A 21.5 G butterfly needle with the plastic needle sheath on 
was inserted into the cord vein, which is the larger vessel compared to the two smaller arteries. The 
needle was then clamped in place with a haemostat, a 20 cc syringe containing Hank's balanced salt 
solution (HBBS) was inserted into the needle. HBBS was pushed through the vein with moderate 
pressure to wash the vein and check for leaks along the cord. The 20 cc syringe was then replaced 
with a 30 cc syringe containing 20 ml collagenase warmed at 37°C. The collagenase solution was 
pushed into cord vein, the other end of the cord was clamped once the first leak passed through. The 
cord was filled with collagenase until a moderate distention of vein was observed, and incubated for 
10 minutes. The cord was then massaged gently, and the second end of the vein was cut with sterile 
scissors. The collagenase solution containing HUVEC was collected in a 50 ml tube, and 
centrifuged at 1500 rpm for 10 minutes at 4°C. The cellular pellet was resuspended in a complete 
E199 medium (Flow Labs, Irvine Scotland, UK) supplemented with 20% heat inactivated FBS 
(PAA Laboratories -GE Healthcare,), 1% L-glutamine (MP Biomedicals, Santa Ana, CA, USA), 
100 U/ml penicillin-streptomycin (MP Biomedicals) and 250 ng/ml Amphotericin B (MP 
Biomedicals). Cells were then seeded into a gelatinized T25 (Corning Incorporated). In all the 
experiments a pool of cells from at least three donors has been used at the first passage. 
When cells reached a confluence, HUVEC were passaged with a 0.25% trypsin/EDTA (Gibco-Life 
Technologies). 
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 Human umbilical vein endothelial cell culture 
HUVEC cell cultures were maintained in complete E199 medium (Flow Labs) supplemented with 
20% heat inactivated FBS (PAA Laboratories-GE Healthcare), 1% L-glutamine (MP Biomedicals 
Inc.), 100 U/ml penicillin-streptomycin (MP Biomedicals) and 250 ng/ml Amphotericin B (MP 
Biomedicals). Confluent cells were passaged with a 0.25% trypsin/EDTA (Gibco-Life 
Technologies). 
 
 Polyethylene glycol-precipitation of immune complexes 
ICs were precipitated from healthy donors‟ and patients‟ sera following the procedure reported by 
Pontes-de-Carvalho
149
. Samples and reagents were kept on ice at all time. One and a half ml tubes 
(Greiner Bio-one, Frickenhausen, Germany) and 5 ml pipette tips (Thermo Scientific) were 
autoclaved the day before use. Briefly, 200 l of serum samples were mixed with 200 l of ice-cold 
5% polyethylene glycol (PEG) 6000 (Sigma-Aldrich) - 0.1M EDTA (Bioscience Inc, La Jolla, CA, 
USA) and incubated overnight at 4°C. The following day, samples were diluted 1:3 with ice-cold 
2.5% PEG 6000 in RPMI to a total volume of 1200 l (Euroclone SpA, Pero, Italy). Five ml pipette 
tubes were cut 2.5 cm from the top; caps of 1.5 ml tubes were removed. A 1000 l solution of 2.5% 
PEG 6000 supplemented with 5% human serum albumin (HAS) (Sigma-Aldrich) was then added in 
each tube, the modified 5 ml pipette tips were then introduced into each tube. Ice-cold diluted serum 
samples (1200 l) were then pipetted against the wall of the 5 ml pipette tip, thus creating two 
layers, with the diluted serum sample on the top of 2.5% PEG-RPMI solution (Figure 7, Panel A). 
Tubes containing the pipette tips were then placed in 15 ml tubes (Falcon, VWR International) and 
centrifuged at 3500 rpm, + 4°C for 20 minutes. After centrifugation, the pipette tips were carefully 
removed from the tubes blocking the upper end with the thumb, a procedure that allows 
withdrawing the tip and its content (Figure 7, Panel B). The remaining pellets, which contained 
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precipitated ICs, were dissolved in 200 l of cold sterile D-PBS (Sigma-Aldrich) to the initial 
serum volume and used fresh at 1:2 dilution factor.  
 
 
Figure 7. Panel A: Ice-cold diluted serum sample was pipetted against the wall of the 5 ml 
pipette tip inserted into a 1.5 ml tube. Panel B: Pipette tip was carefully removed from the 
tubes blocking the upper end with the thumb, in order to withdraw the tip and its content. 
(Original figure) 
 
 Flow cytometry analysis 
TLR3 surface expression on the intact non-permealized fibroblasts and HUVEC was investigated 
by flow cytometry analysis. Briefly, cells were grown to confluence, then detached by 
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trypsin/EDTA and incubated for 30 minutes at 4°C with mouse monoclonal anti-human TLR3 
antibody (5 g/106 cells, Abcam, Cambridge, UK) or with isotype control (20 l/106 cells, 
BioLegend, San Diego, CA, USA), both conjugated with phycoerythrin. After two washes with D-
PBS, 10.000 events were acquired for the analysis by a four-colour cytometer (FACSCalibur; BD 
Biosciences, San Jose, CA, USA). The results were expressed as percentage of gated events, using 
CELLQuest software (BD Biosciences). 
 
 ICAM-1 expression 
ICAM-1 surface levels were evaluated by home-made cell-ELISA. Confluent fibroblast monolayers 
were rested in D-MEM with 1% FBS overnight in 96-well plate; confluent HUVEC monolayers 
were rested in E199 with 1% FBS overnight in 96-well plate. 
Naïve or tlr3-silenced fibroblasts and naïve HUVEC were then stimulated with 100 l/well of: i) 
pathologic ICs (ATA, ACA, ARA and anti-Th/To; dilution 1:2); ii) control ICs (dilution 1:2); iii) 
LPS (1 g/ml); iv) Poly(I:C) (1 g/ml) and v) culture medium. After 48 hours of cell incubation, 
cells were washed twice with HBSS (Sigma-Aldrich), and incubated for 60 minutes at room 
temperature with 100 l/well of murine monoclonal IgG specific for human ICAM-1 (CD54, R&D 
Systems, Minneapolis, MN, USA). The antibody was used at a final dilution of 1:500 in HBSS-FBS 
2.5%. After two additional washes, cells were incubated for 90 minutes at room temperature with 
100 l of phosphatase-conjugated goat anti-mouse IgG (Cappel, Cochranville, PA, USA). The 
secondary antibody was used at a dilution of 1:1000 in HBSS-FBS 10%. After two washes with 
HBSS, 100 l of the enzymatic substrate (p-nitrophenylphosphate in 0.05 M Mg-carbonate buffer 
pH 9.8, Sigma-Aldrich) were added. The optical density (OD) values were evaluated at 405 nm 
after 30 minutes of incubation by a semiautomatic reader (Titertek Multiskan MCC/340, Titertek 
Instruments Inc, Pforzheim, Germany).  
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In tlr3-silenced fibroblasts, ICAM-1 levels were expressed as percentage of Lipofectamine 2000-
transfected cell response. 
 
 Interleukin-6 and interleukin-8 measurement  
Confluent fibroblast monolayers, either naïve or tlr3-silenced, were rested in D-MEM with 1% FBS 
overnight in 96-well plate. Confluent naïve HUVEC monolayers were rested in E199 with 1% FBS 
overnight in 96-well plate. 
Naïve or tlr3-silenced fibroblasts and naïve HUVEC were then stimulated with 100 l/well of: i) 
pathologic ICs (ATA, ACA, ARA and anti-Th/To; dilution 1:2); ii) control ICs (dilution 1:2); iii) 
LPS (1 g/ml); iv) Poly(I:C) (1 g/ml) and v) culture medium. After 48 hours of cell incubation, 
supernatants were collected by centrifugation and frozen at -80°C. IL-6 and IL-8 release was 
evaluated by commercial ELISA kit, according to manufacturer‟s protocol (R&D Systems). The 
OD values were evaluated at 450 nm after 30 minutes of incubation by a semiautomatic reader 
(Titertek Multiskan). IL-6 and IL-8 levels (pg/ml) in cell supernatants were calculated from a 
standard curve obtained using a specific reference preparation.   
In tlr3-silenced fibroblasts, IL-6 and IL-8 levels were expressed as percentage of Lipofectamine 
2000-transfected cell response. 
 
 Matrix metalloproteinase 9 measurement  
Confluent fibroblast monolayers were rested in D-MEM with 1% FBS overnight in 96-well plate. 
Naïve fibroblasts were then stimulated with 100 l/well of: i) pathologic ICs (ATA, ACA, ARA 
and anti-Th/To; dilution 1:2); ii) control ICs (dilution 1:2); iii) LPS (1 g/ml); iv) Poly(I:C) (1 
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g/ml) and v) culture medium. After 48 hours of cell incubation, supernatants were collected by 
centrifugation and frozen at -80°C. MMP-9 release was evaluated by commercial ELISA kit, 
according to manufacturer‟s protocol (R&D Systems). The OD values were evaluated at 450 nm 
after 30 minutes of incubation by a semiautomatic reader (Titertek Multiskan). MMP-9 levels 
(pg/ml) in cell supernatants were calculated from a standard curve obtained using a specific 
reference preparation.   
 
 siRNA transfection  
Stealth
TM
 silencing interference RNAs (siRNAs) targeting human tlr3 were synthesized by Life 
Technologies. Three siRNA duplex oligoribonucleotides were designed to target human tlr3 
(GenBank Accession No. NM_003265.2): i) HSS110815; ii) HSS110816 and iii) HSS110817. 
Scrambled siRNA, with the same nucleotide composition but not the same sequence as tlr3 
siRNAs, was used as negative control (Life Technologies, Carlsbad, CA, USA); BLOCK-iT™ 
Fluorescent Oligo (Life Technologies) was employed to qualitatively assess Oligo uptake in cells 
by fluorescence microscopy with a standard FITC filter (ex=494 nm, em=519 nm green).  
To set siRNA transfection experimental conditions, 90.000 dermal fibroblasts were seeded in 6-well 
polystyrene plates (Corning) and cultered in D-MEM with 10% FBS overnight. Antibiotics were 
not added to culture medium in order to avoid interference with the formation of liposome-RNA 
complexes. Then, cells were transfected with siRNAs (40 nM) complexed with Lipofectamine
TM
 
2000 (2.5 g/ml, Life Technologies), according to manufacturer‟s instructions. Briefly, siRNAs and 
Lipofectamine 2000 pre-diluted in serum free Opti-MEM (Life Technologies) were mixed and 
incubated for 20 minutes at room temperature to allow complex formation. Successively the 
Lipofectamine 2000/siRNA mix was added to Opti-MEM in each well and 5 hours later the 
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medium was replaced by fresh antibiotic-free medium. The efficiency of RNA interference was 
evaluated both as mRNA expression and protein levels at different incubation times.  
For experiments, 5625 fibroblasts per well were seeded in a 96-well plate and cultured in D-MEM-
FBS (10%). The day after, fibroblasts were transfected with the selected tlr3 siRNA for 72 hours 
following the procedure above described. tlr3-silenced skin fibroblasts cultured in a 96-well plate 
were incubated with different stimuli: naïve or tlr3-silenced fibroblasts and naïve HUVEC were 
then stimulated with 100 l/well of: i) pathologic ICs (ATA, ACA, ARA and anti-Th/To; dilution 
1:2); ii) control ICs (dilution 1:2); iii) LPS (1 g/ml); iv) Poly(I:C) (1 g/ml) and v) culture 
medium. Data were expressed as percentage (mean + standard deviation [SD]) of Lipofectamine 
2000-transfected cell response, which was considered as 100%. 
 
 RNA isolation  
Confluent fibroblast monolayers, either naïve or tlr3-silenced, were rested in D-MEM with 1% FBS 
overnight in 96-well plate. Cells were then stimulated with 100 l/well of: i) pathologic ICs (ATA, 
ACA, ARA and anti-Th/To; dilution 1:2); ii) control ICs (dilution 1:2); iii) LPS (1 g/ml); iv) 
Poly(I:C) (1 g/ml) and v) culture medium. Fibroblasts were then lysed with Trizol Reagent (Life 
Technologies) and maintained at -80°C. Total RNA from fibroblasts cultured in different 
experimental conditions was purified using Pure Link
TM
 RNA Mini kit (Life Technologies), 
following the manufacturer‟s instructions. Amplification Grade DNase I (Life Technologies) was 
used to eliminate residual genomic DNA from RNA samples. RNA concentration was evaluated by 
the nanophotometer P-300 (Implen, Westlake Village, CA, USA). The absorbance of a diluted RNA 
sample was measured at 260 and 280 nm. The A260/A280 ratio was used to assess RNA purity; 
only samples with a A260/A280 ratio between 1.8 and 2.1 were considered for experiments. 
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 Reverse transcription reaction 
 A reverse transcription reaction was performed with 1 g RNA using SuperScriptTM First-Strand 
Synthesis System for RT-PCR (Life Technologies). Universal PCR Master Mix No AmpErase 
UNG (Life Technologies) was used for Quantitative Real-Time PCR, performed using ABIPRISM 
7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). 
 
 Real-Time PCR 
Quantification of TLR3, TLR9, IFN- and IFN- mRNA expression in fibroblasts in different 
experimental conditions, was performed with TaqMan Gene Expression Assay (Life Technologies) 
for each target gene (TLR3 Hs01551078_m1, TLR9 Hs00370913_s1, IFN- Hs00855471_g1 and 
IFN- Hs01077958_s1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, HS99999905_m1) 
was used as endogenous reference gene to normalize transcription levels. The expression level of 
target genes was determined by the comparative Ct method normalizing the target to the 
endogenous gene (GAPDH). The PCR conditions were 94°C for 10 minutes, followed by 45 cycles 
of 95°C for 15 seconds, 60°C for 60 seconds and 72°c for 30 seconds. For experiments in naïve 
fibroblasts, the Ct was determined by subtracting the Ct of GAPDH control from the Ct of target 
gene and theCt was calculated as the difference between the Ct of stimulated cells and the Ct 
of cells treated with medium only. For experiments in tlr3-silenced fibroblasts, the Ct was 
determined by subtracting the Ct of GAPDH control from the Ct of target gene and theCt was 
calculated as the difference between the Ct of silenced cells and the Ct of cells treated with 
Lipofectamine 2000 only. The relative value of target to endogenous reference was described as the 
fold change (RQ) =Ct. mRNA expression levels are shown as percentage of Lipofectamine 
2000 transfected cell response. 
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 SDS-PAGE and immunoblotting 
Confluent naïve fibroblast monolayers were rested in D-MEM with 1% FBS overnight in 96-well 
plate. Confluent naïve HUVEC monolayers were rested in E199 with 1% FBS overnight in 96-well 
plate. Cells were then stimulated with 100 l/well of: i) pathologic ICs (ATA, ACA, ARA and anti-
Th/To; dilution 1:2); ii) control ICs (dilution 1:2); iii) LPS (1 g/ml); iv) Poly(I:C) (1 g/ml) and v) 
culture medium. Total proteins were isolated from fibroblasts and HUVEC in different 
experimental conditions using RIPA Lysis Buffer (Sigma-Aldrich) added with Protease and 
Phosphatase inhibitor cocktail (Sigma-Aldrich) as needed. 
Proteins (10 g) were fractionated by NuPAGE BIS-TRIS 4-12% SDS-polyacrylamide pre-cast gel 
electrophoresis (Life Technologies) and then transferred to nitrocellulose using iBlot Transfer 
Stacks Nitrocellulose (Life Technologies) for 7 minutes. The membranes were blocked for two 
hours at room temperature in PBS/0.05% Tween 20 (Bio-Rad Laboratories, Hercules, CA, USA) 
(PT) containing 5% non fat milk powder (Mellin, Milan, Italy) and incubated with the primary 
antibody overnight at 4°C in PT/5% BSA (Sigma-Aldrich). Specific anti-human antibodies 
included: anti-TLR3 (R&D Systems, dilution 1:250); anti-NFB p65 or anti-phosphorylated NFB 
p65 (pNFB p65), anti-p38MAPK or anti-phosphorylated p38MAPK (pp38MAPK) (dilution 
1:1000), anti-p46SAPK-JNK or anti-phosphorylated p46SAPK-JNK (pp46SAPK-JNK) and anti-
p54SAPK-JNK or anti-phosphorylated p54SAPK-JNK (pp54SAPK-JNK) (dilution 1:1000) (Cell 
Signaling Technology, Danvers, MA, USA). 
After washes, the membranes were further incubated for 60 minutes at room temperature with the 
secondary antibody, a goat anti-murine IgG conjugated horseradish peroxidase (HRP, MP 
Biomedicals) diluted 1:2000 in PT/5% non-fat milk powder. After three washes, the antigen-
antibody reactions were detected using the enhanced chemiluminescence (ECL) Plus Western 
Blotting Detection System (Amersham, Uppsala, Sweden). A sheet of autoradiography film 
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(Amersham  Hyperfilm ECL 18x24cm, GE Healthcare Bio-Science, PA, USA) was exposed to the 
membrane in a dark room.  
The detected blots of NFB and p38 were acquired by a scanner (CanoScan 9000 F, Canon, Tokyo, 
Japan), the images were analyzed using the software ImageJ (Java). The relative density of each 
lane was calculated as the ratio of the percent value of the tested sample and the percent value of the 
control sample (medium). Data are expressed as the ratios of the relative density of pNFB 
p65/NFB p65, pp38MAPK/p38MAPK, pp46SAPK-JNK/p46SAPK-JNK and pp54SAPK-
JNK/p54SAPK-JNK.  
 
 Statistical Analysis 
All experiments were run in triplicates.  
The Kolmogorov–Smirnov test of normality was used to verify whether the distribution of variables 
followed a Gaussian pattern. Data with a normal distribution were given as mean ± standard 
deviation [SD], whereas variables with a skewed distribution were be expressed as median and IQR. 
For continuous and normally distributed variables, differences between experimental conditions 
were computed by one way analysis of variance (ANOVA) followed by an appropriate post-hoc 
test. ANOVA for repeated measurement followed by Bonferroni post-hoc test was used to compare 
repeated measurements among different experimental conditions. For continuous and skewed 
distributed variables, differences between different experimental conditions were assessed using 
Kruskal-Wallis test. A p-value less than 0.05 will be considered statistically significant. Statistical 
analysis will be performed using SPSS version 20.  
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Experiments were first aimed at assessing the effects elicited by scleroderma ICs on naïve 
fibroblasts from healthy fibroblasts. This model allowed reproducing in vitro the induction phase of 
the disease. Several mediators involved in scleroderma pathogenesis have been investigated: 
ICAM-1, IL-6, IL-8, MMP-9, IFN- and IFN-.  
 
 ICAM-1 expression in fibroblasts stimulated with scleroderma and control immune 
complexes 
Fibroblast monolayers (96-well plate) were incubated with ICs purified from sera of SSc patients 
with different autoantibody specificities and of healthy subjects (dilution 1:2), TLR3 (Poly(I:C), 1 
µg/ml) and TLR4 synthetic agonists (LPS, 1 µg/ml). All stimuli were prolonged for 48 hours. As 
shown in Figure 8, scleroderma ICs up-regulated ICAM-1 compared to the medium (p<0.01), all to 
a similar extent regardless of the antigenic specificity. To note, no increase in ICAM-1 expression 
was observed after stimulation with ICs from healthy donors. Both TLR ligands induced a 
significant increase in the protein levels of ICAM-1 as compared to the medium (p<0.01).   
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Figure 8. ICAM-1 expression levels (Optical density [OD] values) in skin fibroblasts from 
healthy subjects incubated for 48 hours with LPS (1 g/ml), Poly(I:C) (1 g/ml), scleroderma 
ICs (1:2), control ICs (1:2) as compared to culture medium. Experiments were run in 
triplicates. 
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 IL-6 levels in fibroblasts stimulated with scleroderma and control immune complexes 
Fibroblast monolayers (96 well plate) were stimulated with ICs purified from SSc sera targeting 
different antigenic specificities and from control sera (dilution 1:2), TLR3 (Poly(I:C) [1 µg/ml]) and 
TLR4 synthetic agonists (LPS [1 µg/ml]). Culture supernatants were collected after 48 hour 
activation for IL-6 measurement. As shown in Figure 9, ICs from scleroderma patients up-
regulated IL-6 levels compared to the culture medium (p<0.01). In particular, the strongest up-
regulation was elicited by anti-Th/To ICs. Conversely, ICs isolated from healthy donors did not 
trigger any significant effect on IL-6. Poly(I:C) as well as LPS induced a significant increase in IL-
6 protein levels as compared to the medium (p<0.01).   
 
 
Figure 9. IL-6 protein levels (pg/ml) in the supernatants of skin fibroblasts from healthy 
subjects incubated for 48 hours with LPS (1 g/ml), Poly(I:C) (1 g/ml), scleroderma ICs 
(1:2), control ICs (1:2) as compared to culture medium. Experiments were run in triplicates. 
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 IL-8 levels in fibroblasts stimulated with scleroderma and control immune complexes 
To determine IL-8 levels in the supernatants of fibroblasts in different experimental conditions, skin 
fibroblasts from healthy donors were incubated with ICs containing scleroderma-specific 
autoantibodies (dilution 1:2), ICs purified from serum samples obtained from healthy subjects and 
TLR synthetic ligands (Poly(I:C) [1 µg/ml] and LPS [1 µg/ml]). After 48 hours of stimulation, 
culture supernatants were collected to assess IL-8 levels by ELISA commercial kit. As shown in 
Figure 10, SSc-ICs significantly up-regulated IL-8 levels as compared to the culture medium 
(p<0.01). After incubation with ICs from healthy donors, IL-8 levels were similar to those of cells 
treated with medium alone. The two TLR agonists Poly(I:C) and LPS induced a significant increase 
in IL-8 protein levels compared to the medium (p<0.01).   
 
 
 
 
Figure 10. IL-8 protein levels (pg/ml) in the supernatants of skin fibroblasts from healthy 
subjects incubated for 48 hours with LPS (1 g/ml), Poly(I:C) (1 g/ml), scleroderma ICs 
(1:2), control ICs (1:2) as compared to culture medium. Experiments were run in triplicates. 
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 MMP-9 levels in fibroblasts stimulated with scleroderma and control immune 
complexes 
MMP-9 levels were measured in the supernatants of skin fibroblasts from healthy donors incubated 
with ICs containing scleroderma-specific autoantibodies (dilution 1:2), ICs purified from serum 
samples obtained from healthy subjects and TLR synthetic ligands (Poly(I:C) [1 µg/ml] and LPS [1 
µg/ml]). After 48 hours of stimulation, culture supernatants were collected to assess MMP-9 levels 
by ELISA commercial kit. As shown in Figure 11, SSc-ICs significantly up-regulated MMP-9 
levels as compared to the culture medium (p<0.05). After incubation with ICs from healthy donors, 
MMP-9 levels were similar to those of cells treated with medium alone. Both TLR agonists, 
Poly(I:C) as well as LPS, induced a significant increase in MMP-9 protein levels compared to the 
medium (p<0.05).   
 
 
Figure 11. MMP-9 protein levels (pg/ml) in the supernatants of skin fibroblasts from healthy 
subjects incubated for 48 hours with LPS (1 g/ml), Poly(I:C) (1 g/ml), scleroderma ICs 
(1:2), control ICs (1:2) as compared to culture medium. Experiments were run in triplicates. 
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 IFN- and IFN- mRNA expression in fibroblasts stimulated with scleroderma and 
control immune complexes 
To evaluate the effects of scleroderma ICs on the expression of type I IFNs, skin fibroblasts from 
healthy subjects were stimulated for 24 hours with ICs purified from SSc and healthy subjects 
(dilution 1:2) and with Poly(I:C) (1 µg/ml). As evinced in Figure 12, incubation with scleroderma-
specific ICs triggered a significant increase in both IFN- and IFN- mRNA expression levels. In 
particular, such increase was rather marked for ICs anti-Th/To; a less prominent effect was reported 
for ACA ICs, ARA ICs and –to even a lesser extent- for ATA ICs. ICs from healthy subjects did 
not modulate IFN- and IFN- expression as compared to the medium, whereas Poly(I:C) up-
regulated both IFN- and IFN- mRNA levels (p<0.01).  
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Figure 12. IFN-α e IFN-β mRNA expression levels (expressed as Fold change) in skin 
fibroblasts from healthy donors incubated for 24 hours with LPS (1 g/ml), Poly(I:C) (1 
g/ml), scleroderma ICs (1:2), control ICs (1:2) and culture medium. Experiments were run 
in triplicates. 
 
 
 TLR3 expression on fibroblast cell surface 
Cell surface expression of TLR3 by skin fibroblasts was confirmed by flow cytometry, with 47.4%  
of positive events. 
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 TLR3 and TLR9 mRNA expression in fibroblasts stimulated with scleroderma and 
control immune complexes 
The modulation of TLR3 and TLR9 mRNA expression in skin fibroblast cultures was evaluated by 
Real-Time PCR after 6 hour stimulation with ICs from scleroderma patients, control ICs and TLR3 
agonist, Poly(I:C) (1 g/ml). As shown in Figure 13, SSc-ICs significantly up-regulated the mRNA 
levels of both TLR3 and TLR9. The most marked increase was registered in TLR9 expression, in 
particular after incubation with ARA ICs. Poly(I:C) stimulation drove an up-regulation of its 
receptor TLR3 and, to a lesser extent, of TLR9.  
  
 
 
Figure 13. TLR3 and TLR9 mRNA expression levels (expressed as Fold change) in skin 
fibroblasts from healthy donors incubated for 6 hours with Poly(I:C) (1 g/ml), scleroderma 
ICs (1:2), control ICs (1:2) and culture medium. Experiments were run in triplicates. 
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 Activation of intra-cellular signaling pathways in fibroblasts stimulated with 
scleroderma and control immune complexes 
Fibroblast monolayers (96 well plate) were incubated with ICs purified from sera of SSc patients 
with different autoantibody specificities and of healthy subjects (dilution 1:2) and TLR4 synthetic 
agonist (LPS, 1 µg/ml). All stimuli were prolonged for 30 minutes, total proteins were then 
extracted.  
As shown in Figure 14, stimulation with ARA and anti-Th/To ICs, and also LPS, resulted in a 
significant activation of NFB p65 as compared to the medium (p<0.01). Conversely, fibroblast 
incubation with ATA and ACA ICs, as well as ICs from healthy donors, did not elicit a significant 
NFB phosphorylation.  
 
 
 
Figure 14. Activation of NFB (expressed as pNFB/NFB ratio) in skin fibroblasts from 
healthy subjects incubated for 30 minutes with LPS (1 g/ml), scleroderma ICs (1:2), control 
ICs (1:2) and culture medium. Experiments were run in triplicates. 
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As shown in Figure 15, incubation with ARA and anti-Th/To ICs, as well as with LPS, induced a 
significant activation rate of p38MAPK as compared to the medium (p<0.01). A less striking, but 
still significant, activation of p38MAPK was observed when fibroblasts were stimulated with ATA 
and ACA ICs (p<0.05). Conversely, fibroblast incubation with control ICs did not elicit a 
significant p38MAPK phosphorylation. 
 
 
 
 
Figure 15. Activation of p38 (expressed as pp38/p38 ratio) in skin fibroblasts from healthy 
donors incubated for 30 minutes with LPS (1 g/ml), scleroderma ICs (1:2), control ICs (1:2) 
and culture medium. Experiments were run in triplicates. 
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Stimulation with all scleroderma immune complexes and LPS (p<0.05) induced a significant 
increase in the phosphorylation rate of both p54 and p46, the two phosphorylation sites of SAPK-
JNK. A differential activation was registered in the two phosphorylation sites: ARA ICs emerged as 
the autoantibody specificity responsible of the highest increase in the activation rate of p54 
(p<0.01), whereas anti-Th/To ICs were the scleroderma immune complexes to elicit the most 
significant increase in p46 phosphorylation rate (p<0.01). A not significant modulation of the 
phosphorylation of both subunits of SAPK-JNK was reported in response to control immune 
complexes and medium alone.  
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Figure 16. Activation of p54SAPK-JNK (expressed as pp54SAPK-JNK/p54SAPK-JNK, panel 
A) and p46SAPK-JNK (expressed as pp46SAPK-JNK/p46SAPK-JNK, panel B) in skin 
fibroblasts from healthy donors incubated for 30 minutes with LPS (1 g/ml), scleroderma 
ICs (1:2), control ICs (1:2) and culture medium. Experiments were run in triplicates. 
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To address the potential role of TLR3 in mediating IC-induced effects on fibroblasts, experiments 
were conducted also using tlr3-silenced fibroblasts. 
 
 Evaluation and confirmation of tlr3 silencing efficiency in fibroblasts 
Skin fibroblasts from healthy subjects were transiently transfected with a tlr3 specific siRNA and a 
control siRNA for 72 hours. In preliminary experiments, HSS110816 was selected as the most 
efficient siRNA to silence tlr3. The effect of tlr3 siRNA transfection on mRNA expression was 
quantitatively evaluated by Real-Time PCR. tlr3 siRNA strongly down-regulated TLR3 expression, 
inducing a 95% reduction in its mRNA levels (p<0.01 as compared to Lipofectamine 2000-treated 
cells). Negative control siRNA and Lipofectamine 2000 alone did not affect TLR3 expression 
levels. The modulation of TLR3 expression was evaluated also in tlr3-silenced fibroblasts incubated 
with Poly(I:C) (1 µg/ml) for 24 hours.  
The efficiency of tlr3 silencing was demonstrated also at a protein level by Western blot analysis. 
As shown in Figure 17, the protein signal was strongly attenuated in tlr3 silenced cells (lane 1), tlr3 
silencing also prevented TLR3 up-regulation induced by Poly(I:C) (1 g/ml) stimulation (lane 2). 
The protein signal was reported when cells were incubated with Poly(I:C) (1 g/ml) and Poly(I:C) 
plus Lipofectamine 2000 (lane 3 and 4, respectively). No TLR3 expression could be detected when 
cells were treated with Lipofectamine 2000 and control medium (lane 5 and 6, respectively).  
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1. tlr3 siRNA                                             4. Poly(I:C) + Lipofectamine 2000 
2. tlr3 siRNA + Poly(I:C)                          5. Lipofectamine 2000 
3. Poly(I:C)               6. Culture medium 
 
 
Figure 17. Protein expression of TLR3 in tlr3-silenced untreated or Poly(I:C) (1 g/ml)-
treated fibroblasts and naïve fibroblasts incubated with Poly(I:C) (1 g/ml), Poly(I:C) (1 
g/ml) plus Lipofectamine 2000, Lipofectamine 2000 alone and culture medium. Experiments 
were run in triplicates. 
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 Modulation of ICAM-1 expression in tlr3-silenced fibroblasts stimulated with 
scleroderma and control immune complexes 
tlr3-silenced skin fibroblasts cultured in a 96-well plate were incubated for 48 hours with 
scleroderma and control ICs, Poly(I:C) and LPS. As presented in Figure 18, tlr3 silencing 
significantly attenuated the up-regulation of ICAM-1 induced by ICs from SSc patients and by 
Poly(I:C) (p<0.01) but not LPS. ICAM-1 levels were similar when cells were treated with control 
ICs and culture medium. No difference in ICAM-1 expression level was observed when fibroblasts 
were treated with Lipofectamine 2000.  
 
 
 
Figure 18. Reduction (%) of ICAM-1 expression levels in tlr3-silenced skin fibroblasts from 
healthy subjects incubated for 48 hours with Poly(I:C) (1 g/ml), LPS (1 g/ml), scleroderma 
ICs (1:2) and control ICs (1:2). Experiments were run in triplicates. 
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 Modulation of IL-6 levels in tlr3-silenced fibroblasts stimulated with scleroderma and 
control immune complexes 
tlr3-silenced skin fibroblasts cultured in a 96-well plate were incubated for 48 hours with 
scleroderma and control ICs, Poly(I:C) and LPS. tlr3 silencing significantly affected the up-
regulation of IL-6 modulated by ICs from SSc patients (p<0.01). In particular, the reduction of IL-6 
secretion was rather prominent when cells were incubated with ATA and ARA ICs and less marked 
for ACA-stimulated fibroblasts (p<0.01). Conversely, tlr3 silencing did not attenuate IL-6 levels in 
supernatants from cells treated with control ICs and culture medium. As expected, tlr3 silencing 
significantly inhibited Poly(I:C)- (p<0.01) but not LPS-induced IL-6 secretion. No difference in IL-
6 was registered when fibroblasts were treated with the transfection vector, Lipofectamine 2000. 
The rates of the reduction of IL-6 secretion observed in the different experimental conditions after 
tlr3 silencing are presented in Figure 19.  
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Figure 19. Reduction (%) of IL-6 levels in the supernatants of tlr3-silenced skin fibroblasts 
from healthy subjects incubated for 48 hours with Poly(I:C) (1 g/ml), LPS (1 g/ml), 
scleroderma ICs (1:2) and control ICs (1:2). Experiments were run in triplicates. 
 
 
 Modulation of IL-8 levels in tlr3-silenced fibroblasts stimulated with scleroderma and 
control immune complexes 
IL-8 levels were evaluated by commercial ELISA kit in the supernatants of tlr3-silenced fibroblasts 
cultured in a 96-well plate and incubated for 48 hours with scleroderma and control ICs (dilution 
1:2), Poly(I:C) (1 µg/ml) and LPS (1 µg/ml). tlr3 silencing did not affect IL-8 secretion by 
fibroblasts incubated with ICs isolated from scleroderma serum samples (data not shown). In tlr3-
silenced cells, Poly(I:C) stimulation but not LPS significantly affected IL-8 secretion (p<0.01).           
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Preliminary experiments were also conducted using HUVEC as in vitro model, in order to 
investigate the potential effects elicited by scleroderma ICs on the endothelium, a key player in the 
pathogenesis of scleroderma.   
 
 ICAM-1 expression in HUVEC stimulated with scleroderma and control immune 
complexes 
HUVEC monolayers (96 well plate) were incubated with ICs purified from sera of SSc patients 
with different autoantibody specificities and of healthy controls (dilution 1:2), TLR3 (Poly(I:C), 1 
µg/ml) and TLR4 synthetic agonists (LPS, 1 µg/ml). All stimuli were prolonged for 48 hours. As 
shown in Figure 20, scleroderma ICs up-regulated ICAM-1 as compared to the medium, all to a 
similar extent regardless of the antigenic specificity (p<0.05). No increase in ICAM-1 expression 
was observed after stimulation with ICs from healthy controls. Both TLR ligands induced a 
significant increase in the protein levels of ICAM-1 as compared to the medium (p<0.05).   
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Figure 20. ICAM-1 expression levels (Optical density [OD] values) in HUVEC incubated for 
48 hours with Poly(I:C) (1 g/ml), LPS (1 g/ml),  scleroderma ICs (1:2), control ICs (1:2) as 
compared to culture medium. Experiments were run in triplicates. 
 
 
 TLR3 expression on HUVEC cell surface 
Cell surface expression of TLR3 by HUVEC was confirmed by flow cytometry, with 65.36% of 
positive events. 
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 Activation of p38MAPK in HUVEC stimulated with scleroderma and control immune 
complexes 
HUVEC monolayers (96 well plate) were incubated with ICs purified from sera of SSc patients 
with different autoantibody specificities and of healthy donors (dilution 1:2) and TLR4 synthetic 
agonist (LPS, 1 µg/ml). All stimuli were prolonged for 30 minutes, total proteins were then 
extracted.  
Incubation with ARA and LPS induced a significant activation rate of p38MAPK as compared to 
the medium (p<0.01, Figure 21). Conversely, HUVEC incubation with ATA, ACA and anti-Th/To 
ICs did not result in significant p38MAPK activation. Similarly, control ICs did not elicit a 
significant p38MAPK phosphorylation. 
 
 
Figure 21. Activation of p38 (expressed as pp38/p38 ratio) in HUVEC incubated for 30 
minutes with LPS (1 g/ml), scleroderma ICs (1:2), control ICs (1:2) and culture medium. 
Experiments were run in triplicates. 
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The evidence raised in this study strongly suggests that ICs containing scleroderma-specific 
autoantibodies might exert a pathogenic role in the induction phase of SSc. Indeed, experiments 
envisaged in this work show that scleroderma ICs can disrupt the functionality of fibroblasts and 
endothelial cells, two key players in the promotion of tissue fibrosis. In particular, data suggest that 
incubation with ICs isolated from SSc patients but not from healthy subjects is sufficient to perturb 
fibroblast functionality in vitro, with the induction of a pro-inflammatory and pro-fibrotic 
phenotype. Indeed, upon treatment with scleroderma ICs, skin fibroblasts from healthy donors over-
express ICAM-1, IL-6, IL-8, MMP-9 and type I IFNs, all mediators involved in scleroderma 
pathogenesis. Similar results, unfortunately still incomplete, have been reported in HUVEC, whose 
response to stimulation with SSc-IgG comprises the up-regulation of the adhesion molecule ICAM-
1. These data implicate that SSc ICs might participate in disease pathogenesis early on disease 
course, providing an additional player in the complex interplay between endothelial damage, 
immune deregulation and fibroblast activation that ultimately leads to scleroderma.  
These findings could thus contribute to the collapse of a long-standing dogma in rheumatology, 
namely the non-pathogenicity of scleroderma-specific ANAs. The potential pathogenicity of SSc-
ICs fits well with the strong diagnostic and prognostic predictive value that scleroderma 
autoantibodies exert in clinical settings, with their appearance predating disease onset by few 
months or several years. Noteworthy, positivity for scleroderma-specific autoantibodies has 
emerged as the strongest risk factor influencing the evolution into definite SSc
150
. Nevertheless, a 
very elegant study has recently suggested a causal link between the expression of a mutant ARA 
antigen, the production of specific autoantibodies and SSc onset
77
. Indeed, a striking temporal 
clustering between solid tumours, particularly breast cancers, and the onset of ARA-positive SSc 
has recently emerged
49,50
. Most interestingly, the POLR3A locus, coding for the antigenic target of 
ARA, was altered in cancer tissue specimens from scleroderma patients carrying ARA. This 
mutation implied the synthesis of an immunogen POLR3A gene product, leading to a T-cell driven 
production of specific ARA ultimately resulting in scleroderma onset
77
. Interestingly, patients with 
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SSc exhibit increased DNA damage in peripheral blood cells as evaluated by the comet assay. In 
particular, polymorphic sites in DNA repair genes might affect efficiency in repairing DNA 
damage, resulting in the production of autoantibodies
152
. 
The nuclear localization of target antigens, preventing their accessibility, has been advocated as the 
strongest objections against the pathogenicity of scleroderma antibodies. Dendritic and B cells 
could engage SSc antibodies via FcR; this is not the case of skin fibroblasts and endothelial cells, 
which do not express FcR. Novel perspectives about the potential pathogenic role of SSc peculiar 
autoantibodies have been addressed in previous works, which demonstrated that the nuclear 
antigens targeted by ATA and ACA, respectively topoisomerase I and CENP-B, can adhere to the 
cell surface of cells involved in SSc pathogenesis, resulting in cellular activation upon autoantibody 
binding
70,71,73,75,76
.  
This study addresses an alternative hypothesis to overcome this issue, postulating that the 
interaction of ICs from scleroderma patients with target cells might be mediated by innate immunity 
sensors as TLRs. At this regard, it should be mentioned that scleroderma-specific antibodies bind –
either directly or indirectly via bridge proteins- to nucleic acids. Indeed, ATA target topoisomerase 
I, which is a DNA-nicking enzyme that can also associate with several proteins bound to RNA 
fragments
151
; ACA react against proteins assembled with centromeric DNA; ARA recognize the 
enzyme RNA polymerase, involved in RNA replication while anti-Th/To antibodies bind to 
ribonuclear proteins associated with small RNA fragments
35
. This bulk of observations suggests 
that nucleic acid-containing scleroderma ICs might be engaged by target cells as fibroblasts and 
endothelial cells via TLRs, receptors deputed to sensing nucleic acids, among several PAMPs and 
DAMPs. In this work, research attention was first focused on TLR3, whose role in scleroderma 
pathogenesis has been progressively recognized
136,137
. It should be mentioned that both skin 
fibroblasts and HUVEC express TLR3 not only in intra-cellular compartments but also on the cell 
membrane, as demonstrated by flow cytometry analysis. To address the potential role of TLR3 as 
receptor for scleroderma ICs, dermal fibroblasts obtained from healthy subjects were transiently 
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silenced for tlr3. tlr3-silencing results in a marked –but not complete- reduction of the expression of 
ICAM-1 and IL-6 induced by SSc-ICs, whereas IL-8 synthesis in response to IC incubation is not 
significantly attenuated. As expected, treatment with siRNA does not induce TLR3 activation: this 
synthetic sequence is 25 ribonucleotide long, whereas TLR3 activation requires a minimum length 
of 45 ribonucleotides
135
.     
These data suggest that TLR3 is involved in mediating IC effects on fibroblasts, but additional 
receptors might recognize scleroderma autoantibody/antigen complexes. The observation that 
pathologic ICs induce higher levels of IFN- compared to IFN- might imply the preferential 
involvement of TLRs recruiting MyD88 as adaptor protein. Research attention has been thus 
catalyzed by TLR7, TLR8 and TLR9 as candidate receptors. tlr9-silencing has first been planned, 
and experimental conditions for tlr9-silencing in fibroblasts have already been set.   
When recruitment of intra-cellular mediators is analyzed in response to scleroderma ICs, a 
differential rate of activation is observed for each of the considered antibody specificities. 
Incubation with ARA and anti-Th/To ICs initiates a significant activation of NFB, p38MAPK and 
SAPK-JNK, whereas ATA and ACA stimulation elicits a less significant effect. This is a rather 
interesting finding, since the differential pathogenic effects of scleroderma ICs might account for 
the characteristic clinical phenotypes associated with each autoantibody specificity. 
The nucleic acids incorporated in scleroderma ICs might contain both DNA and RNA: pre-treating 
IC preparation with DNase (Worthington) and RNase (Worthington), an experiment that will be 
shortly performed, will allow to better characterize the nucleic acid composition of different ICs. 
Nucleic acids incorporated in SSc-ICs might be of endogenous as well exogenous nature. DNA and 
RNA are released from damaged and necrotic self-cells, and a defective clearance of apoptotic 
bodies has been reported in many systemic autoimmune conditions. Consistently, the gene coding 
for DNASE1L3, an enzyme involved in DNA fragmentation during apoptosis, has been identified as 
one of the strongest susceptibility loci for SSc
52
. Nucleic acids from pathogens might also be 
incorporated in ICs; interestingly, EBV has been shown to infect the majority of fibroblasts and 
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endothelial cells in the skin of SSc patients, with the expression of EBV noncoding small RNAs and 
the increased expression of immediate-early lytic and latency mRNAs and proteins
145
.   
Many aspects still remain to be clarified, and forthcoming experiments will be aimed at assessing 
the effects elicited by scleroderma ICs on additional pathogenic mediators in both healthy 
fibroblasts and HUVEC. ET-1 (Hs00174961_m1, Life Technologies), mTOR (Hs00234508_m1, 
Life Technologies), PPAR- (Hs01115513_m1, Life Technologies) and IRF3 (Hs01547283_m1, 
Life Technologies) mRNA levels will be tested by Real-Time PCR, CTGF (mouse monoclonal 
anti-human CTGF antibody, Abcam) and -SMA (mouse monoclonal anti-human -SMA 
antibody, Abcam) will be evaluated by Western Blotting, MCP-1 and MMP (MMP-2 and MMP-9) 
secretion in supernatants will be detected by a commercial ELISA kits (R&D Systems) (Figure 20).  
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Figure 20. Mediators involved in scleroderma pathogenesis whose levels in response to SSc-
ICs will be evaluated in future experiments (Original figure). 
TLR: Toll-like Receptor; ss: single stranded; ds: double stranded; CTGF: connective tissue growth factor; MMP: matrix 
metalloproteinase; IL: interleukin; -SMA: -smooth muscle actin; ET-1: endothelin-1; VEGF: vascular endothelial 
growth factor; PTEN: tumour suppressor, phosphatase and tensin homolog; IFN: interferon; TNF-: tumour necrosis 
factor –; MCP-1: monocyte chemotactic protein 1; Blys: B lymphocyte stimulator. 
 
 
Inhibitors of several intra-cellular downstream mediators will be used to further characterize the 
signaling cascade engaged by scleroderma ICs: LY294002 (PI3K inhibitor, Cell Signaling 
Technology), MG132 (NFB inhibitor, Life Technologies), SB202190 (p38MAPK inhibitor, Cell 
Signaling Technology) and mTOR siRNA (s602, s 603 and s604, Life Technologies). To better 
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characterize the cellular localization of TLRs engaged by scleroderma ICs, treatment with 
bafilomycin A1, an endosome acidificator (Millipore, Temecula, CA, USA), will be employed. In 
addition, it would be interesting to investigate the effects elicited by SSc-specific autoantibodies in 
other effector cells involved in the pathogenesis of the disease, such as endothelial cells, T and B 
cells.  
The burden of data presented in this study allows to better understand the role of scleroderma ICs. 
Surely SSc autoantibodies should not be advocated as the only player in scleroderma 
etiopathogenesis; however, they could provide an additional factor contributing to the interplay 
between immunity, vascular damage and excessive fibroblast activation culminating in the tissue 
fibrosis characteristic of scleroderma. The production of autoantibodies might be favoured by 
environmental factors together with a predisposing genetic milieu, as documented by the strong 
association with specific HLA assets and polymorphisms in genes coding for TLRs and down-
stream mediators. The emerging pathogenic role of scleroderma-specific autoantibodies could affect 
every day clinical practice, strongly highlighting the pivotal importance of an early diagnosis. 
Indeed, it might be envisaged that instituting treatment very early on disease course might 
potentially prevent disease evolution. In addition, a further characterization of the pathogenicity of 
scleroderma-specific autoantibodies and down-stream mediators might allow identifying potential 
pharmacological targets: the development of novel agents would be much needed, given the current 
lack of effective treatment.  
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